Form 20-F
falseFY000177801623 0001778016 2021-01-01 2021-12-31 0001778016 2020-12-31 0001778016 2021-12-31 0001778016 2019-01-01 2019-12-31 0001778016 2020-01-01 2020-12-31 0001778016 2019-12-31 0001778016 2018-12-31 0001778016 2019-12-25 2019-12-25 0001778016 2016-10-31 0001778016 2017-12-31 0001778016 2019-01-01 0001778016 2020-04-01 2020-04-30 0001778016 2020-02-10 2020-02-10 0001778016 2021-11-30 0001778016 imab:LaboratoryEquipmentMember 2020-12-31 0001778016 us-gaap:LeaseholdImprovementsMember 2020-12-31 0001778016 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2020-12-31 0001778016 us-gaap:OfficeEquipmentMember 2020-12-31 0001778016 imab:IprAndDTj101Member 2020-12-31 0001778016 imab:TJ103Member 2020-12-31 0001778016 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel3Member 2020-12-31 0001778016 us-gaap:FairValueMeasurementsRecurringMember 2020-12-31 0001778016 imab:PeoplesBankOfChinaMember 2020-12-31 0001778016 imab:TwentyNineteenEmployeeStockOptionPlanMember 2020-12-31 0001778016 imab:ShareIncentivePlanTwoThousandTwentyMember 2020-12-31 0001778016 imab:TwentyNineteenShareIncentivePlanMember 2020-12-31 0001778016 imab:ImabHangzhouMember imab:ImabHongKongMember 2020-12-31 0001778016 imab:DomesticInvestorsMember imab:ImabHangzhouMember 2020-12-31 0001778016 imab:ImabHangzhouMember imab:ManagementHoldcoMember 2020-12-31 0001778016 imab:EsopHoldcoMember imab:ImabHangzhouMember 2020-12-31 0001778016 imab:ImabHangzhouMember 2020-12-31 0001778016 imab:ImabHongKongMember 2020-12-31 0001778016 imab:DomesticInvestorsMember 2020-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2020-12-31 0001778016 imab:TwentyTwentyEmployeeStockOptionPlanMember 2020-12-31 0001778016 imab:ImabHangzhouMember imab:LongTermInvestmentUnderEquityMethodMember imab:RevenueMember 2020-12-31 0001778016 imab:LossFromOperationMember imab:LongTermInvestmentUnderEquityMethodMember imab:ImabHangzhouMember 2020-12-31 0001778016 imab:ImabHangzhouMember imab:LongTermInvestmentUnderEquityMethodMember imab:NetIncomeLossMember 2020-12-31 0001778016 imab:LongTermInvestmentUnderEquityMethodMember imab:ImabHangzhouMember 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareIncentivePlanTwoThousandTwentyMember 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2020-12-31 0001778016 imab:AbbVieMember 2020-12-31 0001778016 imab:JiangsuTaslydiyiPharmaceuticalCoLtdMember 2020-12-31 0001778016 imab:IMabBiopharmaHongKongLimitedMember 2021-12-31 0001778016 imab:IMabShanghaiMember 2021-12-31 0001778016 imab:IMabtianjinMember 2021-12-31 0001778016 imab:ImabbiopharmaUsLtdMember 2021-12-31 0001778016 imab:ZhejiangTianliPharmaceuticalSalesCoLtdMember 2021-12-31 0001778016 imab:LaboratoryEquipmentMember 2021-12-31 0001778016 us-gaap:LeaseholdImprovementsMember 2021-12-31 0001778016 us-gaap:SoftwareAndSoftwareDevelopmentCostsMember 2021-12-31 0001778016 us-gaap:OfficeEquipmentMember 2021-12-31 0001778016 imab:IprAndDTj101Member 2021-12-31 0001778016 imab:TJ103Member 2021-12-31 0001778016 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001778016 us-gaap:FairValueMeasurementsRecurringMember 2021-12-31 0001778016 imab:PeoplesBankOfChinaMember 2021-12-31 0001778016 imab:FederalReserveBankOfNewYorkMember 2021-12-31 0001778016 imab:ShareIncentivePlanTwoThousandTwentyOneMember 2021-12-31 0001778016 imab:OutLicensingAgreementsMember imab:EverestMember 2021-12-31 0001778016 srt:SubsidiariesMember 2021-12-31 0001778016 imab:ShareIncentivePlanTwoThousandTwentyMember 2021-12-31 0001778016 imab:TwentyNineteenEmployeeStockOptionPlanMember 2021-12-31 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember 2021-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2021-12-31 0001778016 imab:PRCMember 2021-12-31 0001778016 imab:InvestorWarrantsMember imab:AmericanDepositarySharesMember 2021-12-31 0001778016 imab:ImabHangzhouMember 2021-12-31 0001778016 imab:DomesticInvestorsMember imab:ImabHangzhouMember 2021-12-31 0001778016 imab:EsopHoldcoMember imab:ImabHangzhouMember 2021-12-31 0001778016 dei:AdrMember us-gaap:PrivatePlacementMember 2021-12-31 0001778016 dei:AdrMember imab:InvestorWarrantsMember 2021-12-31 0001778016 imab:HillhouseEntitiesMember imab:FirstClosingPeriodMember 2021-12-31 0001778016 imab:HillhouseEntitiesMember imab:SecondClosingPeriodMember 2021-12-31 0001778016 imab:EmployeeStockOptionPlanMember 2021-12-31 0001778016 imab:TwentyNineteenShareIncentivePlanMember 2021-12-31 0001778016 imab:RevenueMember imab:LongTermInvestmentUnderEquityMethodMember imab:ImabHangzhouMember 2021-12-31 0001778016 imab:RevenueMember imab:LongTermInvestmentUnderEquityMethodMember imab:OtherEquityInvestmentMember 2021-12-31 0001778016 imab:LossFromOperationMember imab:LongTermInvestmentUnderEquityMethodMember imab:ImabHangzhouMember 2021-12-31 0001778016 imab:LossFromOperationMember imab:LongTermInvestmentUnderEquityMethodMember imab:OtherEquityInvestmentMember 2021-12-31 0001778016 imab:NetIncomeLossMember imab:LongTermInvestmentUnderEquityMethodMember imab:ImabHangzhouMember 2021-12-31 0001778016 imab:NetIncomeLossMember imab:LongTermInvestmentUnderEquityMethodMember imab:OtherEquityInvestmentMember 2021-12-31 0001778016 imab:ImabHangzhouMember imab:LongTermInvestmentUnderEquityMethodMember 2021-12-31 0001778016 imab:OtherEquityInvestmentMember imab:LongTermInvestmentUnderEquityMethodMember 2021-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareIncentivePlanTwoThousandTwentyOneMember 2021-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareIncentivePlanTwoThousandTwentyMember 2021-12-31 0001778016 imab:AbbVieMember 2021-12-31 0001778016 imab:JiangsuTaslydiyiPharmaceuticalCoLtdMember 2021-12-31 0001778016 imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember us-gaap:GeneralAndAdministrativeExpenseMember 2021-12-31 0001778016 imab:ManagementHoldcoMember imab:ImabHangzhouMember 2021-12-31 0001778016 imab:PartnershipAgreementMember 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:LicensingAgreementWithMorphosysAgMember imab:MorphosysMember 2018-01-01 2018-12-31 0001778016 imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember imab:CspcMember 2018-01-01 2018-12-31 0001778016 imab:LicensingAgreementsWithMorphosysMember imab:MorphosysMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-12-31 0001778016 imab:OutLicensingAgreementsMember imab:EverestMember 2018-01-01 2018-12-31 0001778016 imab:CollaborationAgreementWithABLBioMember us-gaap:OperatingExpenseMember 2018-01-01 2018-12-31 0001778016 imab:CollaborationAgreementWithABLBioMember 2018-01-01 2018-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2018-01-01 2018-12-31 0001778016 imab:LicensingAgreementWithABLBioMember 2018-01-01 2018-12-31 0001778016 imab:SupplyOfInvestigationalProductsMember 2019-01-01 2019-12-31 0001778016 imab:LicensingAndCollaborationMember 2019-01-01 2019-12-31 0001778016 dei:AdrMember 2019-01-01 2019-12-31 0001778016 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-12-31 0001778016 us-gaap:RetainedEarningsMember 2019-01-01 2019-12-31 0001778016 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-12-31 0001778016 us-gaap:TreasuryStockMember 2019-01-01 2019-12-31 0001778016 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001778016 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001778016 country:HK 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:TwentyNineteenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:TwentyNineteenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:TwentyNineteenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 imab:TwentyNineteenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:TwentySeventeenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:TwentySeventeenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:TwentySeventeenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2019-01-01 2019-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2019-01-01 2019-12-31 0001778016 imab:ShareIncentivePlan2020Member us-gaap:RestrictedStockMember imab:EquityInLossOfAnAffiliateMember 2019-01-01 2019-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2019-01-01 2019-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001778016 us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:ShareIncentivePlan2020Member 2019-01-01 2019-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:ShareIncentivePlan2020Member 2019-01-01 2019-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:ShareIncentivePlan2020Member 2019-01-01 2019-12-31 0001778016 imab:ShareIncentivePlan2020Member 2019-01-01 2019-12-31 0001778016 imab:LicensingAgreementWithMacroGenicsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:LicensingAgreementWithMorphosysAgMember 2019-01-01 2019-12-31 0001778016 imab:MacroGenicsMember us-gaap:LicensingAgreementsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001778016 imab:LicensingAgreementWithMacroGenicsMember imab:MacroGenicsMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001778016 imab:LicensingAgreementWithMorphosysAgMember imab:MorphosysMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-12-31 0001778016 imab:OtherinlicensingarrangementsMember 2019-01-01 2019-12-31 0001778016 imab:EverestMember imab:CollaborationAgreementWithEverestMember 2019-01-01 2019-12-31 0001778016 imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember us-gaap:OperatingExpenseMember 2019-01-01 2019-12-31 0001778016 imab:CollaborationAgreementWithABLBioMember us-gaap:OperatingExpenseMember 2019-01-01 2019-12-31 0001778016 imab:ABLBioMember imab:CollaborationAgreementWithABLBioMember 2019-01-01 2019-12-31 0001778016 imab:CollaborationAgreementWithABLBioMember 2019-01-01 2019-12-31 0001778016 imab:LicensingAgreementWithABLBioMember us-gaap:OperatingExpenseMember imab:ABLBioMember 2019-01-01 2019-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:ABLBioMember imab:LicensingAgreementWithABLBioMember 2019-01-01 2019-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember srt:DirectorMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2019-01-01 2019-12-31 0001778016 imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember imab:CspcMember 2019-01-01 2019-12-31 0001778016 imab:TaslyPharmaceuticalGroupCoLtdMember imab:ReceiptOfContractResearchOrganizationsMember 2019-01-01 2019-12-31 0001778016 imab:EverestMember 2019-01-01 2019-12-31 0001778016 imab:SeriesBWarrantsSharesMember 2019-01-01 2019-12-31 0001778016 imab:SeriescOneMember imab:SeriesC1ConvertiblePreferredStockMember 2019-01-01 2019-12-31 0001778016 imab:TJ103Member 2019-01-01 2019-12-31 0001778016 imab:SupplyOfInvestigationalProductsMember 2020-01-01 2020-12-31 0001778016 imab:LicensingAndCollaborationMember 2020-01-01 2020-12-31 0001778016 dei:AdrMember 2020-01-01 2020-12-31 0001778016 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-12-31 0001778016 us-gaap:RetainedEarningsMember 2020-01-01 2020-12-31 0001778016 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-12-31 0001778016 us-gaap:CommonStockMember 2020-01-01 2020-12-31 0001778016 country:HK 2020-01-01 2020-12-31 0001778016 imab:PutRightLiabilitiesMember 2020-01-01 2020-12-31 0001778016 us-gaap:ShortTermInvestmentsMember 2020-01-01 2020-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:TwentyNineteenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 imab:TwentyNineteenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:TwentyNineteenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:TwentyNineteenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:TwentySeventeenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:TwentySeventeenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:TwentySeventeenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2020-01-01 2020-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2020-01-01 2020-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2020-01-01 2020-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockMember us-gaap:GeneralAndAdministrativeExpenseMember 2020-01-01 2020-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember 2020-01-01 2020-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:ShareIncentivePlan2020Member 2020-01-01 2020-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:ShareIncentivePlan2020Member 2020-01-01 2020-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:ShareIncentivePlan2020Member 2020-01-01 2020-12-31 0001778016 imab:ShareIncentivePlan2020Member 2020-01-01 2020-12-31 0001778016 imab:LicensingAgreementWithMorphosysMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001778016 imab:ShareIncentivePlanTwoThousandTwentyMember 2020-01-01 2020-12-31 0001778016 imab:MorphoSysAGMember imab:LicensingAgreementWithMorphosysAgMember us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-12-31 0001778016 imab:AbbVieMember imab:LemzoparlimabLicenseMember 2020-01-01 2020-12-31 0001778016 imab:LicensingAgreementWithABLBioMember 2020-01-01 2020-12-31 0001778016 imab:AbbVieMember imab:LemzoparlimabLicenseMember imab:SecondMilestoneMember 2020-01-01 2020-12-31 0001778016 imab:AbbVieMember imab:LemzoparlimabLicenseMember imab:FirstMilestoneMember 2020-01-01 2020-12-31 0001778016 imab:OtherinlicensingarrangementsMember 2020-01-01 2020-12-31 0001778016 imab:AbbVieMember imab:Study2Member 2020-01-01 2020-12-31 0001778016 imab:AbbVieMember imab:Study1Member 2020-01-01 2020-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:GenexineIncMember 2020-01-01 2020-12-31 0001778016 imab:GenexineIncMember 2020-01-01 2020-12-31 0001778016 imab:Study2Member imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember imab:GenexineIncMember 2020-01-01 2020-12-31 0001778016 imab:GenexineIncMember imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember imab:Study1Member 2020-01-01 2020-12-31 0001778016 imab:AbbVieMember 2020-01-01 2020-12-31 0001778016 imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0001778016 us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0001778016 imab:ABLBioMember 2020-01-01 2020-12-31 0001778016 imab:ABLBioMember imab:LicensingAgreementWithABLBioMember us-gaap:OperatingExpenseMember 2020-01-01 2020-12-31 0001778016 imab:ABLBioMember us-gaap:ResearchAndDevelopmentExpenseMember imab:LicensingAgreementWithABLBioMember 2020-01-01 2020-12-31 0001778016 imab:CollaborationAgreementWithABLBioMember 2020-01-01 2020-12-31 0001778016 imab:TwentyTwentyEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 imab:TwentyNineteenShareIncentivePlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:ThirdOneThirdPortionMember imab:OnePerformanceConditionMember 2020-01-01 2020-12-31 0001778016 imab:TwoPerformanceConditionsMember imab:ThirdOneThirdPortionMember us-gaap:RestrictedStockMember 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:ThirdOneThirdPortionMember imab:ThreePerformanceConditionsMember 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:ThirdOneThirdPortionMember imab:FourPerformanceConditionsMember 2020-01-01 2020-12-31 0001778016 imab:ReceiptOfContractResearchOrganizationsMember imab:JiangsuTaslydiyiPharmaceuticalCoLtdMember 2020-01-01 2020-12-31 0001778016 imab:CmabBiopharmaSuzhouIncMember imab:ReceiptOfContractResearchOrganizationsMember 2020-01-01 2020-12-31 0001778016 imab:SeriesBWarrantsSharesMember 2020-01-01 2020-12-31 0001778016 imab:SeriesAConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001778016 imab:SeriesBConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001778016 imab:SeriesCConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001778016 imab:SeriesC1ConvertiblePreferredStockMember 2020-01-01 2020-12-31 0001778016 imab:TJ103Member 2020-01-01 2020-12-31 0001778016 imab:ImabHangzhouMember imab:GroupsShareBasedCompensationMember 2020-01-01 2020-12-31 0001778016 imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember imab:GenexineIncMember 2020-01-01 2020-12-31 0001778016 us-gaap:GrantMember 2020-01-01 2020-12-31 0001778016 imab:TwentyTwentyEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareIncentivePlanTwoThousandTwentyMember 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2020-01-01 2020-12-31 0001778016 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-12-31 0001778016 dei:AdrMember 2021-01-01 2021-12-31 0001778016 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0001778016 dei:BusinessContactMember 2021-01-01 2021-12-31 0001778016 imab:SupplyOfInvestigationalProductsMember 2021-01-01 2021-12-31 0001778016 imab:LicensingAndCollaborationMember 2021-01-01 2021-12-31 0001778016 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0001778016 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0001778016 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0001778016 imab:ZhejiangTianliPharmaceuticalSalesCoLtdMember 2021-01-01 2021-12-31 0001778016 imab:ImabbiopharmaUsLtdMember 2021-01-01 2021-12-31 0001778016 imab:IMabtianjinMember 2021-01-01 2021-12-31 0001778016 imab:IMabShanghaiMember 2021-01-01 2021-12-31 0001778016 imab:IMabBiopharmaHongKongLimitedMember 2021-01-01 2021-12-31 0001778016 us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001778016 us-gaap:WarrantMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001778016 country:HK 2021-01-01 2021-12-31 0001778016 imab:IMobOtherSubsidiariesMember 2021-01-01 2021-12-31 0001778016 imab:CNMember 2021-01-01 2021-12-31 0001778016 us-gaap:ShortTermInvestmentsMember 2021-01-01 2021-12-31 0001778016 imab:PutRightLiabilitiesMember 2021-01-01 2021-12-31 0001778016 imab:LaboratoryEquipmentMember srt:MinimumMember 2021-01-01 2021-12-31 0001778016 imab:LaboratoryEquipmentMember srt:MaximumMember 2021-01-01 2021-12-31 0001778016 imab:SoftwareMember srt:MinimumMember 2021-01-01 2021-12-31 0001778016 srt:MaximumMember imab:SoftwareMember 2021-01-01 2021-12-31 0001778016 imab:OfficeFurnitureAndEquipmentMember 2021-01-01 2021-12-31 0001778016 srt:MinimumMember 2021-01-01 2021-12-31 0001778016 srt:MaximumMember 2021-01-01 2021-12-31 0001778016 imab:SeriesB2PreferredSharesMember 2021-01-01 2021-12-31 0001778016 imab:InvestorWarrantsMember imab:AmericanDepositarySharesMember 2021-01-01 2021-12-31 0001778016 imab:TrancheIOfSeriesBWarrantsMember 2021-01-01 2021-12-31 0001778016 imab:TrancheIiOfSeriesBWarrantsMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001778016 imab:TwentyTwentyOneEmployeeStockOptionPlanMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001778016 us-gaap:EmployeeStockOptionMember imab:TwentyTwentyOneEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:TwentyTwentyEmployeeStockOptionPlanMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareIncentivePlanTwoThousandTwentyMember 2021-01-01 2021-12-31 0001778016 imab:TwentyNineteenEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001778016 imab:TwentyTwentyEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001778016 us-gaap:EmployeeStockOptionMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:TwentyNineteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:TwentyNineteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:TwentyNineteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:TwentyNineteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:TwentySeventeenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:TwentySeventeenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:TwentySeventeenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2021-01-01 2021-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember us-gaap:RestrictedStockMember imab:ShareIncentivePlan2020Member 2021-01-01 2021-12-31 0001778016 imab:ShareIncentivePlan2020Member us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareIncentivePlanTwoThousandTwentyOneMember 2021-01-01 2021-12-31 0001778016 imab:ShareIncentivePlanTwoThousandTwentyOneMember us-gaap:RestrictedStockMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember us-gaap:RestrictedStockMember imab:ShareIncentivePlanTwoThousandTwentyOneMember 2021-01-01 2021-12-31 0001778016 imab:ShareIncentivePlan2020Member us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:ShareIncentivePlan2020Member 2021-01-01 2021-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember imab:ShareIncentivePlan2020Member 2021-01-01 2021-12-31 0001778016 imab:ShareIncentivePlan2020Member 2021-01-01 2021-12-31 0001778016 imab:ShareIncentivePlanTwoThousandTwentyOneMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember imab:ShareIncentivePlanTwoThousandTwentyOneMember 2021-01-01 2021-12-31 0001778016 imab:ShareIncentivePlanTwoThousandTwentyOneMember 2021-01-01 2021-12-31 0001778016 imab:EquityInLossOfAnAffiliateMember 2021-01-01 2021-12-31 0001778016 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-12-31 0001778016 imab:LicensingAgreementWithMacroGenicsMember 2021-01-01 2021-12-31 0001778016 imab:LicensingAgreementWithMorphosysMember 2021-01-01 2021-12-31 0001778016 imab:LicensingAgreementWithMorphosysAgMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:LicensingAgreementWithMorphosysMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:LicensingAgreementWithMacroGenicsMember 2021-01-01 2021-12-31 0001778016 imab:MorphoSysAGMember imab:LicensingAgreementWithMorphosysAgMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001778016 imab:JumpcanAgreementMember 2021-01-01 2021-12-31 0001778016 imab:OtherinlicensingarrangementsMember 2021-01-01 2021-12-31 0001778016 imab:GenexineIncMember imab:LicensingAgreementWithGenexineIncMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember srt:MinimumMember imab:MacroGenicsMember us-gaap:LicensingAgreementsMember 2021-01-01 2021-12-31 0001778016 imab:LicensingAgreementWithGenexineIncMember imab:MacroGenicsMember imab:DevelopmentMilestoneMember 2021-01-01 2021-12-31 0001778016 imab:LicensingAgreementWithGenexineIncMember imab:GenexineIncMember imab:Gxi7Member 2021-01-01 2021-12-31 0001778016 imab:LicensingAgreementWithGenexineIncMember imab:GenexineIncMember us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-12-31 0001778016 imab:LicensingAgreementWithMacroGenicsMember imab:MacroGenicsMember 2021-01-01 2021-12-31 0001778016 imab:AbbVieMember imab:Study1Member 2021-01-01 2021-12-31 0001778016 imab:AbbVieMember imab:Study2Member 2021-01-01 2021-12-31 0001778016 imab:EverestMember imab:OutLicensingAgreementsMember 2021-01-01 2021-12-31 0001778016 imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember us-gaap:OperatingExpenseMember 2021-01-01 2021-12-31 0001778016 us-gaap:OperatingExpenseMember 2021-01-01 2021-12-31 0001778016 imab:GenexineIncMember 2021-01-01 2021-12-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:GenexineIncMember 2021-01-01 2021-12-31 0001778016 imab:ABLBioMember 2021-01-01 2021-12-31 0001778016 imab:CollaborationAgreementWithABLBioMember 2021-01-01 2021-12-31 0001778016 imab:TwentyTwentyOneEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:TwentyTwentyEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:ShareIncentivePlanTwoThousandTwentyMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember imab:ThirdOneThirdPortionMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember imab:ThirdOneThirdPortionMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember imab:ThirdOneThirdPortionMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareBasedCompensationTrancheFourMember imab:ThirdOneThirdPortionMember 2021-01-01 2021-12-31 0001778016 us-gaap:ShareBasedCompensationAwardTrancheOneMember imab:SharePriceBasedAwardsMember 2021-01-01 2021-12-31 0001778016 imab:SharePriceBasedAwardsMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2021-01-01 2021-12-31 0001778016 imab:OnePerformanceConditionMember 2021-01-01 2021-12-31 0001778016 imab:SharePriceBasedAwardsMember 2021-01-01 2021-12-31 0001778016 us-gaap:LeaseholdImprovementsMember 2021-01-01 2021-12-31 0001778016 imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember imab:CspcMember 2021-01-01 2021-12-31 0001778016 imab:ReceiptOfContractResearchOrganizationsMember imab:JiangsuTaslydiyiPharmaceuticalCoLtdMember 2021-01-01 2021-12-31 0001778016 imab:ReceiptOfContractResearchOrganizationsMember imab:ImabHangzhouMember 2021-01-01 2021-12-31 0001778016 imab:CollaborationAgreementWithInvestorsMember 2021-01-01 2021-12-31 0001778016 imab:HillhouseEntitiesMember 2021-01-01 2021-12-31 0001778016 imab:TJ103Member 2021-01-01 2021-12-31 0001778016 imab:PartnershipAgreementMember 2021-01-01 2021-12-31 0001778016 imab:ImabHangzhouMember imab:HLBVMethodMember 2021-01-01 2021-12-31 0001778016 imab:ImabHangzhouMember imab:ManagementHoldcoMember 2021-01-01 2021-12-31 0001778016 imab:ImabHangzhouMember imab:GroupsShareBasedCompensationMember 2021-01-01 2021-12-31 0001778016 imab:ImabHangzhouMember imab:IMabHangzhouShareBasedCompensationMember 2021-01-01 2021-12-31 0001778016 us-gaap:PrivatePlacementMember dei:AdrMember 2021-01-01 2021-12-31 0001778016 imab:InvestorWarrantsMember dei:AdrMember 2021-01-01 2021-12-31 0001778016 imab:HillhouseEntitiesMember imab:SecondClosingPeriodMember 2021-01-01 2021-12-31 0001778016 imab:HillhouseEntitiesMember imab:FirstClosingPeriodMember 2021-01-01 2021-12-31 0001778016 imab:GenexineIncMember imab:Study1Member imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember 2021-01-01 2021-12-31 0001778016 imab:GenexineIncMember imab:StrategicAllianceAgreementWithPtKalbeGenexineBiologicsMember imab:Study2Member 2021-01-01 2021-12-31 0001778016 imab:PaycheckProtectionMember 2021-01-01 2021-12-31 0001778016 imab:PipelineMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember imab:ThirdOneThirdPortionMember 2021-01-01 2021-12-31 0001778016 imab:SecondOneThirdPortionMember imab:TwentyTwentyEmployeeStockOptionPlanMember us-gaap:RestrictedStockMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember imab:TwentyTwentyOneEmployeeStockOptionPlanMember imab:SecondOneThirdPortionMember 2021-01-01 2021-12-31 0001778016 us-gaap:RestrictedStockMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2021-01-01 2021-12-31 0001778016 imab:AbbvieMember 2021-01-01 2021-12-31 0001778016 imab:ImabHangzhouMember imab:ProvisionOfFtaRelatedServicesMember 2021-01-01 2021-12-31 0001778016 imab:ImabHangzhouMember 2021-01-01 2021-12-31 0001778016 imab:MorphoSysAGMember imab:LicensingAgreementWithMorphosysAgMember 2021-01-01 2021-12-31 0001778016 imab:DomesticInvestorsMember imab:ImabHangzhouMember 2021-01-01 2021-12-31 0001778016 imab:ImabHangzhouMember imab:FerringAgreementMember 2021-01-01 2021-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2020-01-17 0001778016 dei:AdrMember us-gaap:IPOMember 2020-01-17 0001778016 imab:CollaborationAgreementWithEverestMember imab:EverestsMember 2020-01-17 0001778016 imab:SeriesAConvertiblePreferredStockMember 2020-01-17 0001778016 imab:ConvertiblePreferredStockSeriesBMember 2020-01-17 0001778016 imab:ConvertiblePreferredStockSeriesBOneUponConversionMember 2020-01-17 0001778016 imab:ConvertiblePreferredStockSeriesB2Member 2020-01-17 0001778016 us-gaap:SeriesCPreferredStockMember 2020-01-17 0001778016 imab:SeriesCOneConvertiblePreferredStockMember 2020-01-17 0001778016 dei:AdrMember us-gaap:IPOMember 2020-01-31 2020-01-31 0001778016 dei:AdrMember 2020-02-10 2020-02-10 0001778016 us-gaap:OverAllotmentOptionMember dei:AdrMember 2020-02-10 0001778016 dei:AdrMember 2020-02-10 0001778016 imab:TasgenGroupMember 2017-07-15 0001778016 imab:ImabHangzhouMember 2020-09-15 2020-12-31 0001778016 imab:ManagementHoldcoMember imab:ImabHangzhouMember 2020-09-15 2020-12-31 0001778016 imab:ImabHangzhouMember imab:HLBVMethodMember 2020-09-15 2020-12-31 0001778016 imab:SeriesC1ConvertiblePreferredStockMember imab:SeriescOneMember 2019-12-31 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember 2019-12-31 0001778016 imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember imab:CspcMember 2018-12-31 0001778016 us-gaap:InvestorMember 2019-10-29 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember 2020-01-17 2020-01-17 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2020-01-17 2020-01-17 0001778016 imab:SeriesAConvertiblePreferredStockMember 2020-01-17 2020-01-17 0001778016 imab:ConvertiblePreferredStockSeriesBMember 2020-01-17 2020-01-17 0001778016 imab:ConvertiblePreferredStockSeriesBOneUponConversionMember 2020-01-17 2020-01-17 0001778016 imab:ConvertiblePreferredStockSeriesB2Member 2020-01-17 2020-01-17 0001778016 us-gaap:SeriesCPreferredStockMember 2020-01-17 2020-01-17 0001778016 imab:SeriesCOneConvertiblePreferredStockMember 2020-01-17 2020-01-17 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember imab:SeniorManagementEmployeesMember 2020-01-17 2020-01-17 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember imab:SeniorManagementEmployeesMember 2020-01-17 2020-01-17 0001778016 imab:TwentyTwentyEmployeeStockOptionPlanMember 2020-07-15 0001778016 us-gaap:RestrictedStockMember 2020-07-15 0001778016 imab:BoardOfDirectorsMember dei:AdrMember 2020-07-15 0001778016 imab:SeriesA1AndA2PreferredStockMember 2016-10-18 2016-10-18 0001778016 imab:ConvertiblePreferredStockSeriesA3Member 2016-10-18 0001778016 imab:SeriesA1AndA2PreferredStockMember 2016-10-18 0001778016 imab:SeriesA3PreferredStockMember 2017-09-06 2017-09-06 0001778016 imab:SeriesA3PreferredStockMember 2017-09-06 0001778016 imab:SeriesBPreferredShareholdersMember 2017-09-22 2017-09-22 0001778016 imab:ConvertiblePreferredStockSeriesBMember 2017-09-22 2017-09-22 0001778016 imab:ConvertiblePreferredStockSeriesB2Member 2017-09-22 0001778016 imab:ConvertiblePreferredStockSeriesBMember 2017-09-22 0001778016 imab:SeriesB2PreferredSharesMember 2018-06-29 0001778016 imab:ConvertiblePreferredStockSeriesBOneUponExerciseMember 2018-06-29 0001778016 imab:ConvertiblePreferredStockSeriesBUponExerciseMember 2018-06-29 0001778016 imab:ConvertiblePreferredStockSeriesBTwoUponExerciseMember 2018-06-29 0001778016 imab:ConvertiblePreferredStockSeriesBOneUponConversionMember 2018-06-29 0001778016 imab:ConvertiblePreferredStockSeriesAThreeUponExerciseMember 2018-06-29 0001778016 imab:TrancheIOfSeriesBWarrantsMember 2018-07-06 0001778016 imab:SeriesBWarrantsSharesMember 2018-07-06 0001778016 us-gaap:SeriesCPreferredStockMember 2018-07-06 0001778016 imab:ConvertiblePreferredStockSeriesBTwoUponExerciseMember 2018-07-06 0001778016 imab:ConvertiblePreferredStockSeriesBOneUponExerciseMember 2018-07-06 0001778016 imab:ConvertiblePreferredStockSeriesBUponExerciseMember 2018-07-06 0001778016 us-gaap:SeriesCPreferredStockMember 2018-07-06 2018-07-06 0001778016 imab:SeriesCOnePreferredStockMember 2019-07-25 0001778016 imab:SeriesCOneConvertiblePreferredStockMember 2019-10-17 2019-10-17 0001778016 imab:SeriesCOneConvertiblePreferredStockMember 2019-10-17 0001778016 imab:SeriesCOneConvertiblePreferredStockMember 2019-11-06 2019-11-06 0001778016 imab:SeriesCOnePreferredStockMember 2019-11-06 2019-11-06 0001778016 imab:SeriesCOneConvertiblePreferredStockMember 2019-11-06 0001778016 srt:MaximumMember 2019-12-25 0001778016 srt:MinimumMember 2019-12-25 0001778016 imab:TemporaryEquityMember us-gaap:PreferredStockMember 2019-01-25 2019-12-25 0001778016 imab:SeriesCOnePreferredStockMember 2019-01-25 2019-12-25 0001778016 imab:SeriesBOnshoreInvestorsMember 2017-09-25 2017-09-25 0001778016 imab:TwoZeroOneEightNotesMember imab:SeriesA3PreferredSharesMember 2018-02-03 2018-02-03 0001778016 imab:SeriesA3PreferredSharesMember imab:ConvertiblePromissoryNotes2018Member 2018-02-03 2018-02-03 0001778016 imab:ConvertiblePromissoryNotes2018Member imab:SeriesB1PreferredSharesMember 2018-02-03 0001778016 imab:SeriesA3PreferredSharesMember imab:ConvertiblePromissoryNotes2018Member 2018-02-03 0001778016 us-gaap:MeasurementInputExercisePriceMember 2020-12-17 0001778016 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-12-17 0001778016 us-gaap:MeasurementInputPriceVolatilityMember 2020-12-17 0001778016 us-gaap:MeasurementInputMaturityMember 2020-12-17 0001778016 imab:GenexineIncMember imab:TwoZeroOneEightNotesMember 2020-12-17 0001778016 imab:WarrantsToPurchaseOrdinarySharesMember 2020-12-17 0001778016 imab:SeriesB2PreferredSharesMember 2018-06-29 2018-07-06 0001778016 imab:WarrantsToPurchaseOrdinarySharesMember 2020-09-11 2020-09-11 0001778016 us-gaap:MeasurementInputExercisePriceMember 2020-09-11 0001778016 us-gaap:MeasurementInputRiskFreeInterestRateMember 2020-09-11 0001778016 us-gaap:MeasurementInputPriceVolatilityMember 2020-09-11 0001778016 us-gaap:MeasurementInputMaturityMember 2020-09-11 0001778016 imab:WarrantsToPurchaseOrdinarySharesMember 2020-09-11 0001778016 imab:WarrantsToPurchaseOrdinarySharesMember 2020-12-17 2020-12-17 0001778016 us-gaap:RestrictedStockMember imab:FoundersMember 2016-10-01 2016-10-31 0001778016 imab:FoundersMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheOneMember 2016-10-01 2016-10-31 0001778016 imab:FoundersMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2016-10-01 2016-10-31 0001778016 imab:FoundersMember us-gaap:RestrictedStockMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2016-10-01 2016-10-31 0001778016 imab:FoundersMember us-gaap:RestrictedStockMember 2016-10-31 0001778016 imab:FoundersMember us-gaap:RestrictedStockMember 2019-10-31 2019-10-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheTwoMember 2017-10-01 2017-10-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedCompensationAwardTrancheThreeMember 2017-10-01 2017-10-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2017-10-01 2017-10-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2017-10-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:MorphosysMember imab:LicensingAgreementWithMorphosysAgMember 2017-01-01 2017-12-31 0001778016 imab:LeiFangMember us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001778016 us-gaap:EmployeeStockOptionMember 2017-01-01 2017-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2020-01-17 2020-01-31 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember 2019-02-22 0001778016 imab:AmendedTwentySeventeenEmployeeStockOptionPlanMember srt:DirectorMember 2019-02-22 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember srt:DirectorMember 2019-02-22 0001778016 us-gaap:ShareBasedCompensationAwardTrancheOneMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2019-02-22 2019-02-22 0001778016 us-gaap:ShareBasedCompensationAwardTrancheTwoMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2019-02-22 2019-02-22 0001778016 imab:TwentyTwentyEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2019-02-22 2019-02-22 0001778016 imab:DrzangMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2019-02-22 2019-02-22 0001778016 srt:DirectorMember imab:AmendedTwentySeventeenEmployeeStockOptionPlanMember 2019-02-22 2019-02-22 0001778016 srt:DirectorMember 2019-02-22 2019-02-22 0001778016 imab:MorphosysMember imab:LicensingAgreementWithMorphosysAgMember 2017-11-17 2017-11-17 0001778016 imab:GenexineIncMember imab:LicensingAgreementWithGenexineIncMember 2018-01-01 2018-01-01 0001778016 imab:LicensingAgreementWithGenexineIncMember us-gaap:ResearchAndDevelopmentExpenseMember imab:GenexineIncMember 2018-01-01 2018-01-31 0001778016 imab:LicensingAgreementWithGenexineIncMember imab:GenexineIncMember 2018-01-01 2018-01-31 0001778016 imab:MorphoSysAGMember imab:LicensingAgreementWithMorphosysAgMember 2020-08-01 2020-08-31 0001778016 imab:OtherinlicensingarrangementsMember 2021-12-31 2021-12-31 0001778016 imab:EverestMember imab:OutLicensingAgreementsMember 2019-11-04 0001778016 imab:EverestMember imab:CollaborationAgreementWithEverestMember 2020-01-31 0001778016 imab:ABLBioMember imab:LicensingAgreementWithABLBioMember 2018-07-01 2018-07-31 0001778016 imab:LicensingAgreementWithABLBioMember imab:ABLBioMember imab:SalesMilestonesMember 2018-07-31 2018-07-31 0001778016 imab:LicensingAgreementWithABLBioMember imab:ABLBioMember imab:ClinicalMilestonesMember 2018-07-31 2018-07-31 0001778016 imab:LicensingAgreementWithABLBioMember imab:ABLBioMember 2018-07-31 2018-07-31 0001778016 imab:CollaborationAgreementWithABLBioMember imab:ABLBioMember 2018-07-31 2018-07-31 0001778016 imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember imab:CspcMember 2019-02-28 2019-02-28 0001778016 imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember imab:CspcMember 2019-09-30 2019-09-30 0001778016 imab:AbbVieMember 2020-09-03 2020-09-03 0001778016 imab:ClinicalMilestonesMember imab:AbbVieMember 2020-09-03 2020-09-03 0001778016 imab:AbbVieMember 2021-03-31 0001778016 imab:ImabHangzhouMember 2020-07-31 0001778016 imab:ImabHangzhouMember 2019-07-31 0001778016 us-gaap:SubsequentEventMember us-gaap:CommonClassBMember imab:VivereMember 2022-02-22 2022-02-22 0001778016 imab:PartnershipAgreementMember 2021-07-31 0001778016 imab:PartnershipAgreementMember 2021-08-31 0001778016 us-gaap:ResearchAndDevelopmentExpenseMember imab:LicensingAgreementWithMacroGenicsMember imab:MacroGenicsMember 2021-09-30 2021-09-30 0001778016 imab:LicensingAgreementWithCSPCPharmaceuticalGroupLimitedMember imab:CspcMember 2022-01-31 2022-01-31 0001778016 imab:TwentyTwentyOneEmployeeStockOptionPlanMember us-gaap:RestrictedStockMember 2021-05-28 0001778016 imab:TwentyTwentyOneEmployeeStockOptionPlanMember 2021-05-28 0001778016 imab:ImabHongKongMember 2019-06-16 0001778016 imab:CollaborationAgreementsWithTraconPharmaceuticalsIncMember 2021-02-28 0001778016 imab:ImabHangzhouMember 2020-09-15 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2018-12-31 0001778016 us-gaap:RetainedEarningsMember 2018-12-31 0001778016 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001778016 us-gaap:TreasuryStockMember 2018-12-31 0001778016 us-gaap:CommonStockMember 2018-12-31 0001778016 imab:SeriescOneMember imab:SeriesC1ConvertiblePreferredStockMember 2018-12-31 0001778016 imab:SeriesAConvertiblePreferredStockMember 2018-12-31 0001778016 imab:SeriesBConvertiblePreferredStockMember 2018-12-31 0001778016 imab:SeriesCConvertiblePreferredStockMember 2018-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember 2019-12-31 0001778016 imab:SeriesAConvertiblePreferredStockMember 2019-12-31 0001778016 imab:SeriesBConvertiblePreferredStockMember 2019-12-31 0001778016 imab:SeriesCConvertiblePreferredStockMember 2019-12-31 0001778016 imab:SeriesC1ConvertiblePreferredStockMember 2019-12-31 0001778016 us-gaap:RetainedEarningsMember 2019-12-31 0001778016 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0001778016 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0001778016 us-gaap:CommonStockMember 2019-12-31 0001778016 imab:PutRightLiabilitiesMember 2019-12-31 0001778016 us-gaap:ShortTermInvestmentsMember 2019-12-31 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember 2020-12-31 0001778016 us-gaap:ShortTermInvestmentsMember 2020-12-31 0001778016 imab:PutRightLiabilitiesMember 2020-12-31 0001778016 imab:SeriesAConvertiblePreferredStockMember 2020-12-31 0001778016 imab:SeriesC1ConvertiblePreferredStockMember imab:SeriescOneMember 2020-12-31 0001778016 imab:SeriesBConvertiblePreferredStockMember 2020-12-31 0001778016 imab:SeriesCConvertiblePreferredStockMember 2020-12-31 0001778016 us-gaap:RestrictedStockMember imab:ShareIncentivePlanTwoThousandTwentyMember 2019-12-31 0001778016 us-gaap:RetainedEarningsMember 2020-12-31 0001778016 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001778016 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001778016 us-gaap:CommonStockMember 2020-12-31 0001778016 us-gaap:ShortTermInvestmentsMember 2021-12-31 0001778016 imab:PutRightLiabilitiesMember 2021-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2020-12-31 0001778016 imab:TwentyEighteenEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2020-12-31 0001778016 imab:TwentySeventeenEmployeeStockOptionPlanMember us-gaap:EmployeeStockOptionMember 2021-12-31 0001778016 us-gaap:EmployeeStockOptionMember imab:TwentyEighteenEmployeeStockOptionPlanMember 2021-12-31 0001778016 imab:TwentyTwentyEmployeeStockOptionPlanMember 2021-12-31 0001778016 us-gaap:RestrictedStockMember imab:TwentyTwentyEmployeeStockOptionPlanMember 2020-12-31 0001778016 us-gaap:RetainedEarningsMember 2021-12-31 0001778016 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001778016 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001778016 us-gaap:CommonStockMember 2021-12-31 iso4217:CNY iso4217:USD xbrli:shares xbrli:pure utr:Year utr:Day utr:Month iso4217:USD xbrli:shares iso4217:CNY xbrli:shares
Table of Contents
 
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 
FORM
20-F
 
 
(Mark One)
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
 
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2021.
OR
 
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
OR
 
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of event requiring this shell company report
                    
For the transition period from
                    
to
                    
Commission file number:
001-39173
 
 
I-MAB
(Exact Name of Registrant as Specified in Its Charter)
 
 
N/A
(Translation of Registrant’s Name Into English)
Cayman Islands
(Jurisdiction of Incorporation or Organization)
55
th
– 56
th
Floor, New Bund Center, 555 West Haiyang Road, Pudong District
Shanghai, 200124
People’s Republic of China
(Address of Principal Executive Offices)
John Long, Chief Financial Officer
55
th
– 56
th
Floor, New Bund Center, 555 West Haiyang Road, Pudong District
Shanghai, 200124
People’s Republic of China
Phone: +86
21-6057-8000
Email:
john.long@i-mabbiopharma.com
(Name, Telephone, Email and/or Facsimile number and Address of Company Contact Person)
 
 
Securities registered or to be registered pursuant to Section 12(b) of the Act:
 
Title of Each Class
 
Trading
Symbol
 
Name of Each Exchange
On Which Registered
American depositary shares, each ten
(10) American depositary shares representing twenty-three (23) ordinary shares
Ordinary shares, par value US$0.0001 per share*
 
IMAB
 
The Nasdaq Stock Market LLC
(The Nasdaq Global Market)
The Nasdaq Stock Market LLC
(The Nasdaq Global Market)
 
*
Not for trading, but only in connection with the listing on the Nasdaq Global Market of American depositary shares.
Securities registered or to be registered pursuant to Section 12(g) of the Act:
None
(Title of Class)
Securities for which there is a reporting obligation pursuant to Section 15(d) of the Act:
None
(Title of Class)
 
 
Indicate the number of outstanding shares of each of the issuer’s classes of capital or common stock as of the close of the period covered by the annual report:
183,826,753
 
ordinary shares outstanding, par value of US$0.0001 per share, excluding
1,223,839
ordinary shares issued to our depositary bank for bulk issuance of ADSs reserved for future issuances upon the exercising or vesting of awards granted under our share incentive plans, as of December 31, 2021.
Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    ☒  
Yes
    ☐  No
If this report is an annual or transition report, indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.    ☐  Yes    ☒  
No
Note – Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 from their obligations under those Sections Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    ☒  
Yes
    ☐  No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    ☒  
Yes
    ☐  No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated
filer, or an emerging growth company. See definition of “large accelerated filer,” “accelerated filer,” and “emerging growth company” in Rule
12b-2
of the Exchange Act.
 
Large accelerated filer      Accelerated filer     Non-accelerated filer  
           
                 Emerging growth company  
If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards† provided pursuant to Section 13(a) of the Exchange Act.  ☐
†The term “new or revised financial accounting standard” refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.
Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accountant firm that prepared or issued its audit report.  
Indicate by check mark which basis of accounting the registrant has used to prepare the financial statements included in this filing:
 
U.S. GAAP  ☒           International Financial Reporting Standards as issued             Other  ☐
            by the International Accounting Standards Board            
If “Other” has been checked in response to the previous question, indicate by check mark which financial statement item the registrant has elected to follow.    ☐  Item 17    ☐  Item 18
If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule
12b-2
of the Exchange Act).    ☐  Yes    
  No
(APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS)
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.    ☐  Yes    ☐  No
 
 
 

TABLE OF CONTENTS
 
 
  
Page
 
  
 
1
 
  
 
2
 
  
 
3
 
  
 
3
 
  
 
3
 
  
 
3
 
  
 
71
 
  
 
159
 
  
 
159
 
  
 
176
 
  
 
197
 
  
 
202
 
  
 
203
 
  
 
203
 
  
 
213
 
  
 
214
 
  
 
217
 
  
 
217
 
  
 
217
 
  
 
217
 
  
 
218
 
  
 
218
 
  
 
218
 
  
 
219
 
  
 
219
 
  
 
219
 
  
 
219
 
  
 
220
 
  
 
220
 
  
 
221
 
  
 
221
 
  
 
221
 
  
 
221
 
 
i

INTRODUCTION
Unless otherwise indicated and except where the context otherwise requires, references in this annual report on Form
20-F
to:
 
   
“ADRs” refer to the American depositary receipts that evidence our ADSs;
 
   
“ADSs” refer to our American depositary shares, each ten (10) ADSs represent twenty-three (23) ordinary shares;
 
   
“China” or “the PRC” refers to the People’s Republic of China, excluding, for the purposes of this annual report only, Hong Kong, Macau and Taiwan, and “Greater China” does not exclude Hong Kong, Macau and Taiwan;
 
   
“China Portfolio” refers to our investigational drugs of which we
in-license
Greater China rights from reputable global biopharmaceutical companies and rely on our own research and development capabilities to advance into pivotal clinical trials and commercialize in Greater China with an aim for near-term product launch;
 
   
“Global Portfolio” refers to our own proprietary novel or differentiated drug candidates that we are advancing towards clinical validation in the United States;
 
   
“I-Mab,”
“we,” “us,” “our company” and “our” refer to
I-Mab,
a Cayman Islands exempted company, and its subsidiaries;
 
   
“RMB” refers to the legal currency of China;
 
   
“shares” or “ordinary shares” refer to our ordinary shares, par value US$0.0001 per share; and
 
   
“US$,” “U.S. dollars,” “$,” and “dollars” refer to the legal currency of the United States.
 
1

Table of Contents
FORWARD-LOOKING STATEMENTS
This annual report on Form
20-F
contains forward-looking statements that relate to our current expectations and views of future events. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigations Reform Act of 1995.
You can identify some of these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. We have based these forward-looking statements largely on our current expectations and projections about future events that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements include statements relating to:
 
   
the timing of initiation and completion, and the progress of our drug discovery and research programs;
 
   
the timing and likelihood of regulatory filings and approvals;
 
   
our ability to advance our drug candidates into drugs, and the successful completion of clinical trials;
 
   
the approval, pricing and reimbursement of our drug candidates;
 
   
the commercialization of our drug candidates;
 
   
the market opportunities and competitive landscape of our drug candidates;
 
   
the payment, receipt and timing of any milestone payments in relation to the licensing agreements;
 
   
estimates of our costs, expenses, future revenues, capital expenditures and our needs for additional financing;
 
   
our ability to attract and retain senior management and key employees;
 
   
our future business development, financial condition and results of operations;
 
   
future developments, trends, conditions and competitive landscape in the industry and markets in which we operate;
 
   
our strategies, plans, objectives and goals and our ability to successfully implement these strategies, plans, objectives and goals;
 
   
our ability to consummate the listings of our securities on other stock exchanges;
 
   
our ability to continue to maintain our market position in China’s biopharmaceutical and biotechnology industries;
 
   
our ability to identify and integrate suitable acquisition targets;
 
   
changes to regulatory and operating conditions in our industry and markets; and
 
   
potential impact of
COVID-19
pandemic on our current and future business development, financial condition and results of operations.
You should read this annual report and the documents that we refer to in this annual report and have filed as exhibits to this annual report completely and with the understanding that our actual future results may be materially different from what we expect. Other sections of this annual report discuss factors which could adversely impact our business and financial performance. Moreover, we operate in an evolving environment. New risk factors emerge from time to time and it is not possible for our management to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We qualify all of our forward-looking statements by these cautionary statements.
You should not rely upon forward-looking statements as predictions of future events. The forward-looking statements made in this annual report relate only to events or information as of the date on which the statements are made in this annual report. Except as required by law, we undertake no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events.
Our reporting currency is Renminbi, or RMB. Unless otherwise noted, all translations from RMB to U.S. dollars and from U.S. dollars to RMB in this annual report are made at a rate of RMB6.3726 to US$1.00, the exchange rate in effect as of December 30, 2021 as set forth in the H.10 statistical release of The Board of Governors of the Federal Reserve System. We make no representation that any RMB or U.S. dollar amounts could have been, or could be, converted into U.S. dollars or RMB, as the case may be, at any particular rate, or at all.
 
2

Table of Contents
PART I
 
ITEM 1.
IDENTITY OF DIRECTORS, SENIOR MANAGEMENT AND ADVISERS
Not applicable.
 
ITEM 2.
OFFER STATISTICS AND EXPECTED TIMETABLE
Not applicable.
 
ITEM 3.
KEY INFORMATION
Our Holding Company Structure
I-Mab
is not an operating company but a Cayman Islands holding company with operations primarily conducted by its subsidiaries based in China and the United States. We and our subsidiaries face various legal and operational risks and uncertainties related to doing business in mainland China. A significant part of our business operations in China are conducted through our subsidiaries in the PRC, and we and our subsidiaries are subject to complex and evolving PRC laws and regulations. For example, we and our subsidiaries in the PRC face risks associated with regulatory approvals on offshore offerings and the lack of inspection on our auditors by the Public Company Accounting Oversight Board (United States), or PCAOB, which may impact our ability to conduct certain businesses, accept foreign investments, or list on a United States or other foreign exchange. These risks could result in a material adverse change in our operations and the value of our ADSs, significantly limit or completely hinder our ability to offer or continue to offer securities to investors, or cause such securities to significantly decline in value. For a detailed description of risks related to doing business in China, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China.”
PRC government’s significant authority in regulating our operations and its oversight and control over offerings conducted overseas by, and foreign investment in, China-based issuers could significantly limit or completely hinder our ability to offer or continue to offer securities to investors. Implementation of industry-wide regulations, including data security or anti-monopoly related regulations, in this nature may cause the value of such securities to significantly decline. For more details, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The PRC government’s significant oversight and discretion over our business operations could result in a material adverse change in our operations and the value of our ADSs.”
Risks and uncertainties arising from the legal system in China, including risks and uncertainties regarding the enforcement of laws and quickly evolving rules and regulations in China, could result in a material adverse change in our operations and the value of our ADSs. For more details, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Uncertainties with respect to the PRC legal system could materially and adversely affect us.”
Permissions Required from the PRC Authorities
We conduct our business in China primarily through our subsidiaries in China. Our operations in China are governed by PRC laws and regulations. As of the date of this annual report, our PRC subsidiaries have obtained the requisite licenses and permits from the PRC government authorities that are material for their business operations in China. Given the uncertainties of interpretation and implementation of relevant laws and regulations and the enforcement practice by relevant government authorities, we may be required to obtain additional licenses, permits, filings or approvals for the functions and services of our platform in the future.
Furthermore, in connection with our historical issuance of securities to foreign investors, under the current PRC laws, regulations and regulatory rules, as of the date of this annual report, we and our PRC subsidiaries, (i) are not required to obtain permissions from the China Securities Regulatory Commission, or the CSRC, (ii) are not required to go through cybersecurity review by the Cyberspace Administration of China, or the CAC, and (iii) have not received or were denied such permissions by the CSRC or the CAC.
 
3

Table of Contents
However, the PRC government has recently indicated an intent to exert more oversight and control over offerings that are conducted overseas and/or foreign investment in China-based issuers. For more detailed information, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The approval of and filing with the CSRC or other PRC government authorities may be required in connection with our offshore offerings under PRC law, and, if required, we cannot predict whether or for how long we will be able to obtain such approval or complete such filing.”
The Holding Foreign Companies Accountable Act
The Holding Foreign Companies Accountable Act, or HFCAA, was signed into law on December 18, 2020. The HFCAA states if the SEC determines that an issuer has filed audit reports issued by a registered public accounting firm that has not been subject to inspection by the PCAOB, the issuer will be identified as a “Commission-Identified Issuer” under the HFCAA after the filing of its annual report. In March 2022, the SEC published its first list of “Commission-Identified Issuers.” We expect to be included on this list after our annual report on Form 20-F for the fiscal year ended December 31, 2021 is filed. However, the inclusion on this list will not immediately result in the delisting of our shares or ADS from the securities exchange. Delisting pursuant to the HFCAA will only occur if the registered public accounting firm that issues audit reports cannot be fully inspected by the PCAOB for three years, or pending legislation to be shorten to two consecutive years.
There have been dialogues between the relevant regulators in China and the United States to resolve the underlying issue. In April 2022, the CSRC, Ministry of Finance of the People’s Republic of China, or the MoF, National Administration of State Secrets Protection, and National Archives Administration of China jointly circulated the proposed revisions to the currently effective Provisions on Strengthening Confidentiality and Archives Administration for Overseas Securities Offering and Listing, or the Confidentiality and Archives Administration Provisions. The proposed revisions are intended to be a step forward in potentially facilitating inspections by the PCAOB. CSRC stated that China stays committed to supporting eligible China-based companies of all types to list or offer securities in overseas markets, and the revised Confidentiality and Archives Administration Provisions would further strengthen the compliance of such companies and promote healthy and orderly overseas securities offering and listing. Although no agreement has been reached between the U.S. and China regulatory authorities, we will continue to actively monitor the latest regulatory developments.
Nevertheless, we have initiated action plans, in response to the delisting risk, to engage a U.S.-based independent registered public accounting firm as our principal auditor that is subject to the inspection by the PCAOB. This firm would also need to comply with the applicable rules and regulations concerning information confidentiality and archives administration for compliance purposes in China. At the earliest, such change may take place for our annual report for the year ended December 31, 2022, which is ahead of the deadline currently contemplated under the HFCAA.
For more details and risks regarding the HFCAA, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—The PCAOB is currently unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections over our auditor deprives our investors with the benefits of such inspections” and “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—Our ADSs will be prohibited from trading in the United States under the Holding Foreign Companies Accountable Act, or the HFCAA, in 2024 if the PCAOB is unable to inspect or fully investigate auditors located in China, or in 2023 if proposed changes to the law are enacted. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment.”
Cash and Asset Flows through Our Organization
Although other means are available for us to obtain financing at the holding company level, our ability to pay dividends to the shareholders and to service any debt it may incur may depend upon dividends paid by our PRC subsidiaries. If any of our subsidiaries incurs debt on its own behalf in the future, the instruments governing such debt may restrict its ability to pay dividends to
I-Mab.
In addition, our PRC subsidiaries are permitted to pay dividends to
I-Mab
only out of their retained earnings, if any, as determined in accordance with PRC accounting standards and regulations. Further, our PRC subsidiaries are required to make appropriations to certain statutory reserve funds or may make appropriations to certain discretionary funds, which are not distributable as cash dividends except in the event of a solvent liquidation of the companies. For more details, see “Item 5. Operating and Financial Review and Prospects—B. Liquidity and Capital Resources—Holding Company Structure.”
 
4

Table of Contents
Under PRC laws and regulations, our PRC subsidiaries are subject to certain restrictions with respect to paying dividends or otherwise transferring any of their net assets to us. Remittance of dividends by a wholly foreign-owned enterprise out of China is also subject to examination by the banks designated by SAFE. The amounts restricted include the
paid-up
capital and the statutory reserve funds of our PRC subsidiaries, totaling RMB455.0 million, RMB455.0 million and RMB486.9 million (US$76.4 million) as of December 31, 2019, 2020 and 2021, respectively. Furthermore, cash transfers from our PRC subsidiaries to entities outside of China are subject to PRC government control of currency conversion. Shortages in the availability of foreign currency may temporarily delay the ability of our PRC subsidiaries to remit sufficient foreign currency to pay dividends or other payments to us, or otherwise satisfy their foreign currency denominated obligations. For the years ended December 31, 2019, 2020 and 2021, no dividends or distributions were made to
I-Mab
by our subsidiaries. For risks relating to the fund flows of our operations in China, see “Item 3. Key Information—D. Risk Factors—Risks Related to Doing Business in China—We may rely on dividends and other distributions on equity paid by our PRC subsidiaries to fund any cash and financing requirements we may have, and any limitation on the ability of our PRC subsidiaries to make payments to us could have a material and adverse effect on our ability to conduct our business.”
Under PRC law,
I-Mab
may provide funding to our PRC subsidiaries only through capital contributions or loans, subject to satisfaction of applicable government registration and approval requirements. In the years ended December 31, 2019, 2020 and 2021,
I-Mab
extended loans with outstanding principal amount of RMB6.3 million, RMB776.2 million and RMB1,079.6 million (US$169.4 million), respectively, to our intermediate holding companies and subsidiaries.
I-Mab
has not declared or paid any cash dividends, nor does it have any present plan to pay any cash dividends on our ordinary shares in the foreseeable future. We currently intend to retain most, if not all, of our available funds and any future earnings to operate and expand our business. See “Item 8. Financial Information—A. Consolidated Statements and Other Financial Information—Dividend Policy.” For PRC and United States federal income tax considerations of an investment in our ADSs, see “Item 10. Additional Information—E. Taxation.”
Selected Financial Data
As of December 31, 2021, we had cash, cash equivalents, and short-term investments of RMB4.3 billion (US$671.1 million), compared with RMB4.8 billion as of December 31, 2020. Our cash balance provides us with adequate funding to support our key business for at least the next three years based on our current estimation, taking our current cash position together with the expected upcoming milestone payments from the previous
out-licensing
deals and collaborations.
The following selected consolidated statements of comprehensive income (loss) data for the years ended December 31, 2019, 2020 and 2021, selected consolidated balance sheet data as of December 31, 2020 and 2021 and selected consolidated statements of cash flow data for the years ended December 31, 2019, 2020 and 2021 have been derived from our audited consolidated financial statements included elsewhere in this annual report. The selected consolidated statements of comprehensive loss data for the years ended December 31, 2017 and 2018, selected consolidated balance sheet data as of December 31, 2017, 2018 and 2019, and selected consolidated statements of cash flow data for the years ended December 31, 2017 and 2018 have been derived from our audited consolidated financial statements that are not included in this annual report. Our consolidated financial statements are prepared and presented in accordance with accounting principles generally accepted in the United States of America, or U.S. GAAP.
Our historical results do not necessarily indicate results expected for any future periods. The selected consolidated financial data should be read in conjunction with, and are qualified in their entirety by reference to, our audited consolidated financial statements and related notes and “Item 5. Operating and Financial Review and Prospects” below.
 
5

Table of Contents
   
For the Year Ended December 31,
 
   
2017
   
2018
   
2019
   
2020
   
2021
 
   
RMB
   
RMB
   
RMB
   
RMB
   
RMB
   
US$
 
                                     
    (in thousands, except for share and per share data)  
Selected Consolidated Statements of Comprehensive Income (Loss) Data:
           
Revenues
           
Licensing and collaboration revenue
    11,556       53,781       30,000       1,542,668       40,115       6,295  
Supply of investigational products
    —         —         —         —         47,911       7,518  
Total revenues
    11,556       53,781       30,000       1,542,668       88,026       13,813  
Cost of revenues
    —         —         —         —         (46,432     (7,286
Expenses
           
Research and development expenses
(1)
    (267,075     (426,028     (840,415     (984,689     (1,212,958     (190,340
Administrative expenses
(1)
    (25,436     (66,391     (654,553     (402,409     (899,943     (141,221
Income (loss) from operations
    (280,955     (438,638     (1,464,968     155,570       (2,071,307     (325,034
Interest income
    858       4,597       30,570       24,228       21,333       3,348  
Interest expense
    (5,643     (11,695     (2,991     (957     —         —    
Other income (expenses), net
    1,527       (16,780     (20,205     412,892       83,162       13,050  
Equity in loss of affiliates
(1)
    —         —         —         (108,587     (367,883     (57,729
Fair value change of warrants
    (14,027     61,405       5,644       —         —         —    
Income (loss) before income tax expense
    (298,240     (401,111     (1,451,950     483,146       (2,334,695     (366,365
Income tax benefit (expense)
    —         (1,722     —         (12,231     3,154       495  
Net income (loss) attributable to
I-Mab
    (298,240     (402,833     (1,451,950     470,915       (2,331,541     (365,870
Deemed dividend to Series
C-1
preferred shareholders at extinguishment of Series
C-1
Preferred Shares
    —         —         (5,283     —         —         —    
Deemed dividend to Series
B-1,
B-2
and C preferred shareholders at modification of Series
B-1,
B-2
and C Preferred Shares
    —         —         (27,768     —         —         —    
Net income (loss) attributable to ordinary shareholders
    (298,240     (402,833     (1,485,001     470,915       (2,331,541     (365,870
Other comprehensive income (loss)
           
Foreign currency translation adjustments, net of nil tax
    5,918       53,689       10,747       (120,920     (135,717     (21,297
Total comprehensive income (loss) attributable to
I-Mab
    (292,322     (349,144     (1,441,203     349,995       (2,467,258     (387,167
Net income (loss) attributable to ordinary share-holders
    (298,240     (402,833     (1,485,001     470,915       (2,331,541     (365,870
Weighted-average number of ordinary shares used in calculating net income (loss) per share
           
Basic
    5,742,669       6,529,092       7,381,230       134,158,824       174,707,055       174,707,055  
Diluted
    5,742,669       6,529,092       7,381,230       157,231,652       174,707,055       174,707,055  
Net income (loss) per share attributable to ordinary shareholders
           
Basic
    (51.93     (61.70     (201.19     3.51       (13.35     (2.09
Diluted
    (51.93     (61.70     (201.19     3.00       (13.35     (2.09
Net income (loss) per ADS attributable to ordinary shareholders
           
Basic
    (119.44     (141.91     (462.74     8.07       (30.71     (4.82
Diluted
    (119.44     (141.91     (462.74     6.90       (30.71     (4.82
 
Note:
 
(1)
Share-based compensation expenses were allocated as follows:
 
                        
                        
                        
                        
                        
                        
    
For the Year Ended December 31,
 
    
2017
    
2018
    
2019
    
2020
    
2021
 
    
RMB
    
RMB
    
RMB
    
RMB
    
RMB
    
US$
 
                                           
    
(in thousands)
 
Research and development expenses
  
 
2,112
 
  
 
1,056
 
  
 
470
 
  
 
284,431
 
  
 
201,926
 
  
 
31,687
 
Administrative expenses
  
 
4,927
 
  
 
2,464
 
  
 
514,733
 
  
 
209,033
 
  
 
406,683
 
  
 
63,817
 
Equity in loss of affiliates
  
 
—  
 
  
 
—  
 
  
 
—  
 
  
 
32,707
 
  
 
13,267
 
  
 
2,082
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
Total
  
 
7,039
 
  
 
3,520
 
  
 
515,203
 
  
 
526,171
 
  
 
621,876
 
  
 
97,586
 
  
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
 
 
6

Table of Contents
The following table presents our selected consolidated statements of balance sheet data as of the dates indicated:
 
    
As of December 31,
 
    
2017
   
2018
   
2019
   
2020
   
2021
 
    
RMB
   
RMB
   
RMB
   
RMB
   
RMB
   
US$
 
                                      
     (in thousands)  
Selected Consolidated Statements of Balance Sheet Data:
            
Current assets:
            
Cash and cash equivalents
     307,930       1,588,278       1,137,473       4,758,778       3,523,632       552,935  
Restricted cash
     104,783       92,653       55,810       —         —         —    
Accounts receivable
     —         —         —         130,498       33,081       5,191  
Contract assets
     —         11,000       —         227,391       253,780       39,824  
Short-term investments
     —         —         32,000       31,530       753,164       118,188  
Inventories
     —         —         —         —         27,237       4,274  
Prepayments and other receivables
     12,633       88,972       136,036       195,467       190,824       29,944  
Other financial assets
     266,245       255,958       —         —         —         —    
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total current assets
     691,591       2,036,861       1,361,319       5,343,664       4,781,718       750,356  
Property, equipment and software
     22,336       27,659       30,069       25,272       45,716       7,174  
Operating lease
right-of-use
assets
     —         —         16,435       14,997       112,781       17,698  
Intangible assets
     148,844       148,844       148,844       120,444       119,666       18,778  
Goodwill
     162,574       162,574       162,574       162,574       162,574       25,511  
Investment accounted for using the equity method
     —         —         —         664,832       352,106       55,253  
Other
non-current
assets
     —         —         18,331       2,010       26,634       4,179  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total assets
  
 
1,025,345
 
 
 
2,375,938
 
 
 
1,737,572
 
 
 
6,333,793
 
 
 
5,601,195
 
 
 
878,949
 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total liabilities
  
 
309,151
 
 
 
415,684
 
 
 
668,090
 
 
 
706,648
 
 
 
1,041,635
 
 
 
163,454
 
Total mezzanine equity
  
 
1,015,989
 
 
 
2,915,358
 
 
 
3,104,177
 
 
 
—  
 
 
 
—  
 
 
 
—  
 
Shareholders’ deficit
            
Ordinary shares (US$0.0001 par value, 800,000,000 shares authorized as of December 31, 2020 and 2021, respectively; 164,888,519 shares issued and outstanding as of December 31, 2020, and 183,826,753 shares issued and outstanding as of December 31, 2021, respectively)
     6       6       6       114       126       20  
Treasury stock
     (1     (1     —         —         —         —    
Additional
paid-in
capital
     52,369       —         389,379       7,701,116       9,100,777       1,428,110  
Accumulated other comprehensive income (loss)
     5,691       59,380       70,127       (50,793     (186,510     (29,267
Accumulated deficit
     (357,860     (1,014,489     (2,494,207     (2,023,292     (4,354,833     (683,368
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total shareholders’ equity/(deficit)
  
 
(299,795
 
 
(955,104
 
 
(2,034,695
 
 
5,627,145
 
 
 
4,559,560
 
 
 
715,495
 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Total liabilities, mezzanine equity and shareholders’ equity/(deficit)
  
 
1,025,345
 
 
 
2,375,938
 
 
 
1,737,572
 
 
 
6,333,793
 
 
 
5,601,195
 
 
 
878,949
 
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
The following table presents our selected consolidated statements of cash flow data for the years indicated:
 
    
For the Year Ended December 31,
 
    
2017
   
2018
   
2019
   
2020
   
2021
 
    
RMB
   
RMB
   
RMB
   
RMB
   
RMB
   
US$
 
                                      
     (in thousands)  
Selected Consolidated Statements of Cash Flow Data:
            
Net cash (used in) generated from operating activities
     (252,157     (280,705     (867,982     433,558       (973,093     (152,700
Net cash (used in) generated from investing activities
     (157,665     9,500       212,462       (201,901     (727,206     (114,114
Net cash generated from financing activities
     758,585       1,479,669       152,709       3,440,481       593,924       93,200  
Effect of exchange rate changes on cash and cash equivalents and restricted cash
     (132     59,754       15,163       (106,643     (128,771     (20,207
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Net increase (decrease) in cash, cash equivalents and restricted cash
     348,631       1,268,218       (487,648     3,565,495       (1,235,146     (193,821
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
Cash, cash equivalents and restricted cash, beginning of the year
     64,082       412,713       1,680,931       1,193,283       4,758,778       746,756  
Cash, cash equivalents and restricted cash, end of the year
     412,713       1,680,931       1,193,283       4,758,778       3,523,632       552,935  
  
 
 
   
 
 
   
 
 
   
 
 
   
 
 
   
 
 
 
 
7

Table of Contents
A.
Reserved
B.
Capitalization and Indebtedness
Not applicable.
C.
Reasons for the Offer and Use of Proceeds
Not applicable.
D.
Risk Factors
Summary of Risk Factors
An investment in our ADSs or ordinary shares involves significant risks. Below is a summary of material risks we face, organized under relevant headings. These risks are discussed more fully in “Item 3. Key Information—D. Risk Factors.”
Risks Related to Our Financial Position and Need for Additional Capital
 
   
We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
 
   
We have incurred net losses in the past and we may not be able to maintain profitability in the future.
 
   
We recorded net cash outflow from operating activities in the past. We may need to obtain additional financing to fund our operations. If we are unable to obtain such financing, we may be unable to complete the development and commercialization of our major drug candidates.
Risks Related to Clinical Development of Our Drug Candidates
 
   
Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
 
   
We depend substantially on the success of our drug candidates, all of which are in
pre-clinical
or clinical development, and our ability to identify additional drug candidates. If we are unable to successfully identify new drug candidates, complete clinical development, obtain regulatory approval and commercialize our drug candidates, or experience significant delays in doing so, our business will be materially harmed.
 
   
We may not be able to identify, discover or
in-license
new drug candidates, and may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable, or for which there is a greater likelihood of success.
Risks Related to Obtaining Regulatory Approval for Our Drug Candidates
 
   
All material aspects of the research, development and commercialization of pharmaceutical products are heavily regulated.
 
   
The regulatory approval processes of the NMPA, the FDA and other comparable regulatory authorities are time-consuming and may evolve over time, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed.
 
8

Table of Contents
   
The failure to obtain patent term extension and data exclusivity for approved pharmaceutical products could increase the risk of generic competition with our products.
Risks Related to Commercialization of Our Drug Candidates
 
   
Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
 
   
We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our drug candidates.
 
   
The manufacture of biopharmaceutical products is a complex process which requires significant expertise and capital investment, and if we encounter problems in sourcing manufacturing capabilities or manufacturing our future products, our business could suffer.
Risks Related to Our Reliance on Third Parties
 
   
As we rely on third parties to conduct our
pre-clinical
studies and clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.
 
   
We expect to rely on third parties to manufacture at least a portion of our drug candidate supplies, and we intend to rely on third parties for at least a portion of the manufacturing process of our drug candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product or fail to do so at acceptable quality levels or prices.
Risks Related to Our Intellectual Property
 
   
If we are unable to obtain and maintain patent and other intellectual property protection for our drug candidates, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our ability to successfully commercialize any product or technology may be adversely affected.
 
   
We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout the world, including in the PRC.
 
   
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for
non-compliance
with these requirements.
Risks Related to Our Industry, Business and Operations
 
   
Our future success depends on our ability to attract, retain and motivate senior management and qualified scientific employees.
 
   
We will need to increase the size and capabilities of our organization, and we may experience difficulties in managing our growth.
 
   
The data and information that we gather in our research and development process could be inaccurate or incomplete, which could harm our business, reputation, financial condition and results of operations.
Risks Related to Doing Business in China
 
   
The PRC government’s significant oversight and discretion over our business operations could result in a material adverse change in our operations and the value of our ADSs.
 
9

Table of Contents
   
The PCAOB is currently unable to inspect our auditor in relation to their audit work performed for our financial statements and the inability of the PCAOB to conduct inspections over our auditor deprives our investors with the benefits of such inspections.
 
   
Our ADSs will be prohibited from trading in the United States under the Holding Foreign Companies Accountable Act, or the HFCAA, in 2024 if the PCAOB is unable to inspect or fully investigate auditors located in China, or in 2023 if proposed changes to the law are enacted. The delisting of our ADSs, or the threat of their being delisted, may materially and adversely affect the value of your investment.
 
   
The approval of and filing with the CSRC or other PRC government authorities may be required in connection with our offshore offerings under PRC law, and, if required, we cannot predict whether or for how long we will be able to obtain such approval or complete such filing.
General Risks Related to Our ADSs
 
   
The trading price of our ADSs may be volatile, which could result in substantial losses to you.
 
   
We may face an increased risk of securities class action litigation.
Risks Related to Our Financial Position and Need for Additional Capital
We have a limited operating history, which may make it difficult to evaluate our current business and predict our future performance.
We are a clinical stage biopharmaceutical company with a limited operating history. Our operations to date have focused on organizing and staffing our operations, business planning, raising capital, establishing our intellectual property portfolio and conducting
pre-clinical
and clinical trials of our drug candidates. We have not yet demonstrated an ability to successfully manufacture, obtain marketing approvals for or commercialize our drug candidates. We have no products approved for commercial sale and have not generated any revenue from the sales of our commercial products. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.
We are focused on the discovery and development of innovative drugs for the treatment of various immuno-oncological and immuno-inflammatory diseases. Our limited operating history, particularly in light of the rapidly evolving drug research and development industry in which we operate and the changing regulatory and market environments we encounter, may make it difficult to evaluate our prospects for future performance. As a result, any assessment of our future performance or viability is subject to significant uncertainty. We will encounter risks and difficulties frequently experienced by early-stage companies in rapidly evolving fields as we seek to transition to a company capable of supporting commercial activities. If we do not address these risks and difficulties successfully, our business will suffer.
We have incurred net losses in the past and we may not be able to maintain profitability in the future.
Investment in the development of biopharmaceutical products is highly speculative as it entails substantial upfront capital expenditures and significant risks that a drug candidate may fail to demonstrate efficacy and/or safety to gain regulatory or marketing approvals or become commercially viable. To date, we have financed our activities primarily through public and private placements. While we have generated revenue from licensing and collaboration deals, we have only started to generate revenue from supply of investigational products since 2021, and we may continue to incur significant research and development expenses and other expenses related to our ongoing operations. As a result, we had incurred a net loss of RMB1,452.0 million in 2019, a net income of RMB470.9 million in 2020 and a net loss of RMB2,331.5 million (US$365.9 million) in 2021, respectively. Substantially all of our net losses have resulted from costs incurred in connection with our research and development programs and from general and administrative costs associated with our operations.
 
10

Table of Contents
We cannot assure you that we will be able to generate net profits in the future. Our ability to achieve and maintain profitability depends in large part on our ability to
out-license
some of our commercialization rights and execute our product commercialization strategies as our business further grows in scale. Accordingly, we intend to continue to invest for the foreseeable future in certain activities relating to our development, including, but not limited to, the following:
 
   
conducting clinical trials of our drug candidates;
 
   
manufacturing clinical trial materials through contract manufacturing organizations, or CMOs, in and out of China;
 
   
seeking regulatory approvals for our drug candidates;
 
   
commercializing our drug candidates for which we have obtained marketing approval;
 
   
completing the construction of and maintaining our manufacturing facilities;
 
   
hiring additional clinical, operational, financial, quality control and scientific personnel;
 
   
establishing a sales, marketing and commercialization team for any future products that have obtained regulatory approval;
 
   
seeking to identify additional drug candidates;
 
   
obtaining, maintaining, expanding and protecting our intellectual property portfolio;
 
   
enforcing and defending any intellectual property-related claims; and
 
   
acquiring or
in-licensing
other drug candidates, intellectual property and technologies.
Typically, it takes many years to develop one new drug from the time it is discovered to when it becomes available for treating patients. During the process, we may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend partially on the rate of the future growth of our expenses, our ability to generate revenues and the timing and amount of milestone payments and other payments that we receive from or pay to third parties. If any of our drug candidates fails during clinical trials or does not gain regulatory approval, or, even if approved, fails to achieve market acceptance, our business may not become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods thereafter. Our prior losses and expected future losses have had, and will continue to have, an adverse effect on our working capital and shareholders’ equity.
We recorded net cash outflow from operating activities in the past. We may need to obtain additional financing to fund our operations. If we are unable to obtain such financing, we may be unable to complete the development and commercialization of our major drug candidates.
Since our inception, our operations have consumed substantial amounts of cash. We had raised over US$400 million in
pre-IPO
financing in the past and received total net proceeds of approximately US$105.3 million from our initial public offering. We spent RMB868.0 million in net cash to finance our operations in 2019, generated RMB433.6 million in net cash from our operations in 2020, and spent RMB973.1 million (US$152.7 million) in net cash to finance our operations in 2021.
We expect our expenses to increase significantly in connection with our ongoing activities, particularly as we advance the clinical development of our clinical-stage drug candidates, continue the research and development of our
pre-clinical
stage drug candidates and initiate additional clinical trials of, and seek regulatory approval for, these and other future drug candidates.
In addition, if we obtain regulatory approvals for any of our drug candidates, we expect to incur significant commercialization expenses relating to product manufacturing, marketing, sales and distribution and post-approval commitments to continue monitoring the efficacy and safety data of our future products on the market. In particular, costs that may be required for the manufacture of any drug candidate that has received regulatory approval may be substantial as we may need to modify or increase our production capacity in the future at manufacturing facilities. We have incurred and may continue to incur expenses as we create additional infrastructure to support our operations as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations through public or private equity offerings, debt financing, collaborations or licensing arrangements or other sources. If we are unable to raise capital when needed or on acceptable terms, we could be forced to delay, limit, reduce or terminate our research and development programs or any future commercialization efforts.
 
 
11

Table of Contents
COVID-19
has spread globally and the World Health Organization (WHO) has declared it a pandemic. While still evolving, the
COVID-19
pandemic has brought uncertainties and interruptions to global economy and caused significant volatility across the financial markets, which had a cooling effect on the financing and investing activities in general. We believe that our current cash and cash equivalents, together with our cash generated from operating activities, financing activities, our initial public offering and private placement, will be sufficient to meet our present anticipated working capital requirements and capital expenditures. However, if the impact of the
COVID-19
and volatility in the financial markets continue, our financing activities in future to raise additional capital may be materially and adversely affected, which may in turn have an adverse effect on our ability to meet our working capital requirement and our liquidity. For other risks related to the
COVID-19,
see “—Our business and results of operations could be adversely affected by public health crisis (including the
COVID-19
global pandemic) and natural catastrophes or other disasters outside of our control in the locations in which we, our suppliers, CROs, CMOs and other contractors operate.”
Raising additional capital may cause dilution to the interests to the holders of our ADSs and our shareholders, restrict our operations or require us to relinquish rights to our technologies or drug candidates.
We may seek additional funding through a combination of equity offerings, debt financings, collaborations, licensing arrangements, strategic alliances or partnerships and government grants or subsidies. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a holder of our ADSs. The incurrence of additional indebtedness or the issuance of certain equity securities could give rise to increased fixed payment obligations and also result in certain additional restrictive covenants, such as limitations on our ability to incur additional debt or issue additional equity, limitations on our ability to acquire or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. In addition, the issuance of additional equity securities, or the possibility of such issuance, may cause the market price of our ADSs to decline.
In the event we enter into collaborations or licensing arrangements in order to raise capital, we may be required to accept unfavorable terms, including relinquishing or licensing to a third party our rights to technologies or drug candidates on unfavorable terms, which we would have otherwise sought to develop or commercialize on our own or reserve for future potential arrangements when we are more likely to achieve more favorable terms.
Risks Related to Clinical Development of Our Drug Candidates
Clinical development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. While our exclusive focus is to develop drug candidates with potential to become novel or highly differentiated drugs in China and globally, we cannot guarantee that we are able to achieve this for any of our drug candidates. Failure can occur at any time during the clinical development process. The results of
pre-clinical
studies and early clinical trials of our drug candidates may not be predictive of the results of later-stage clinical trials. Drug candidates during later stages of clinical trials may fail to show the desired results in safety and efficacy despite having progressed through
pre-clinical
studies and initial clinical trials and despite the level of scientific rigor in the study, design and adequacy of execution. In some instances, there can be significant variability in safety and/or efficacy results among different trials of the same drug candidate due to numerous factors, including, but not limited to, differences in individual patient conditions, including genetic differences, and other compounding factors, such as other medications or
pre-existing
medical conditions.
In the case of any trials we conduct, results may differ from earlier trials due to the larger number of clinical trial sites and additional countries and languages involved in such trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to a lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. We cannot guarantee that our future clinical trial results will be favorable based on currently available clinical and
pre-clinical
data.
 
12

Table of Contents
We depend substantially on the success of our drug candidates, all of which are in
pre-clinical
or clinical development, and our ability to identify additional drug candidates. If we are unable to successfully identify new drug candidates, complete clinical development, obtain regulatory approval and commercialize our drug candidates, or experience significant delays in doing so, our business will be materially harmed.
Our business will depend on the successful development, regulatory approval and commercialization of our drug candidates for the treatment of patients with our targeted indications, all of which are still in
pre-clinical
or clinical development, and other new drug candidates that we may identify and develop. As of the date of this annual report, we have obtained investigational new drug (IND) approvals from the NMPA for ten of our drug candidates, felzartamab, olamkicept, efineptakin alfa, lemzoparlimab, uliledlimab, plonmarlimab, eftansomatropin alfa, enoblituzumab, TJ210 and
TJ-CD4B.
In addition, we have obtained IND approvals from the FDA for six of our drug candidates, lemzoparlimab, uliledlimab, plonmarlimab, TJ210,
TJ-L14B
and
TJ-CD4B;
from the Taiwan Food and Drug Administration (the “TFDA”) for two of our drug candidates, felzartamab and olamkicept; and from the Korea Ministry of Food and Drug Safety (the “MFDS”) for olamkicept. However, we cannot guarantee that we are able to obtain regulatory approvals for our other existing drug candidates in a timely manner, or at all. In addition, none of our drug candidates has been approved for marketing in China or any other jurisdiction. Each of our drug candidates will require additional
pre-clinical
and/ or clinical development, regulatory approvals in multiple jurisdictions, development of manufacturing supply and capacity, substantial investment and significant marketing efforts before we generate any revenue from product sales.
The success of our drug candidates will depend on several factors, including, but not limited to, the successful completion of
pre-clinical
and/or clinical trials or studies, receipt of regulatory approvals from applicable regulatory authorities for planned clinical trials, future clinical trials or drug registrations, establishing adequate manufacturing capabilities and capacities, commercialization of our existing drug candidates, hiring sufficient technical experts to oversee all development and regulatory activities and license renewal and meeting of the safety requirements.
If we do not achieve one or more of these in a timely manner or at all, we could experience significant delays in our ability to obtain approval for our drug candidates, which would materially harm our business and we may not be able to generate sufficient revenues and cash flows to continue our operations. As a result, our financial condition, results of operations and prospects will be materially and adversely harmed.
We may not be able to identify, discover or
in-license
new drug candidates, and may allocate our limited resources to pursue a particular drug candidate or indication and fail to capitalize on drug candidates or indications that may later prove to be more profitable, or for which there is a greater likelihood of success.
Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our existing drug candidates, the success of our business depends in part upon our ability to identify, license, discover, develop, or commercialize additional drug candidates. Research programs to identify new drug candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or drug candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to identify, discover or
in-license
new drug candidates for clinical development and commercialization for a number of reasons, including, without limitation, the following:
 
   
our research or business development methodology or search criteria and process may be unsuccessful in identifying potential drug candidates;
 
   
our potential drug candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval; and
 
   
it may take greater human and financial resources to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs than we possess, thereby limiting our ability to diversify and expand our drug portfolio.
 
13

Table of Contents
Because we have limited financial and managerial resources, we focus on research programs and drug candidates for specific indications. As a result, we may forgo or delay pursuit of opportunities with other drug candidates or for other indications that later may prove to have greater commercial potential or a greater likelihood of success. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities.
Accordingly, there can be no assurance that we will ever be able to identify additional therapeutic opportunities for our drug candidates or to develop suitable potential drug candidates through internal research programs, which could materially adversely affect our future growth and prospects.
If we encounter delays or difficulties enrolling patients in our clinical trials, our clinical development progress could be delayed or otherwise adversely affected.
We may not be able to initiate or continue clinical trials for our drug candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the NMPA, the FDA, or similar regulatory authorities, or if there are delays in the enrollment of eligible patients as a result of the competitive clinical enrollment environment. The inability to enroll a sufficient number of patients who meet the applicable criteria for our clinical trials would result in significant delays. As of the date of this annual report, we have initiated clinical trials for olamkicept in South Korea and Greater China, for efineptakin alfa and eftansomatropin alfa and enoblituzumab in China, for felzartamab in Greater China, for TJ210 and
TJ-L14B
in the United States, for lemzoparlimab, plonmarlimab, uliledlimab and
TJ-CD4B
in China and the United States.
In addition, some of our competitors have ongoing clinical trials for drug candidates that treat the same indications as our drug candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in the clinical trials of our competitors’ drug candidates, which may further delay our clinical trial enrollments.
Patient enrollment for our clinical trials may be affected by other factors, including, but not limited to, the following:
 
   
severity of the disease under investigation;
 
   
total size and nature of the relevant patient population;
 
   
design and eligibility criteria for the clinical trial in question;
 
   
perceived risks and benefits of the drug candidate under study;
 
   
our resources to facilitate timely enrollment in clinical trials;
 
   
patient referral practices of physicians;
 
   
availability of competing therapies also undergoing clinical trials;
 
   
our investigators’ or clinical trial sites’ efforts to screen and recruit eligible patients; and
 
   
proximity and availability of clinical trial sites for prospective patients.
Even if we are able to enroll a sufficient number of patients in our clinical trials, delays in patient enrollment may result in increased costs or may affect the timing or outcome of the planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our drug candidates.
If clinical trials of our drug candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our drug candidates.
Before obtaining regulatory approval for the sale of our drug candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our drug candidates in humans. We may experience numerous unexpected events during, or as a result of, clinical trials that could delay or prevent our ability to receive regulatory approval or commercialize our drug candidates, including, without limitation:
 
14

Table of Contents
   
regulators, institutional review boards, or IRBs, or ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;
 
   
our inability to reach agreements on acceptable terms with prospective CROs and trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
 
   
manufacturing issues, including problems with manufacturing, supply quality, compliance with good manufacturing practice, or GMP, or obtaining sufficient quantities of a drug candidate from third parties for use in a clinical trial;
 
   
clinical trials of our drug candidates may produce negative or inconclusive results, and we may decide to conduct additional clinical trials or abandon drug development programs, or regulators may require us to do so;
 
   
the number of patients required for clinical trials of our drug candidates may be larger than we anticipate, enrollment may be insufficient or slower than we anticipate or patients may drop out at a higher rate than we anticipate;
 
   
our third-party contractors, including clinical investigators, may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all;
 
   
we might have to suspend or terminate clinical trials of our drug candidates for various reasons, including a finding of a lack of clinical response or other unexpected characteristics or a finding that participants are being exposed to unacceptable health risks;
 
   
regulators, IRBs or ethics committees may require that we or our investigators suspend or terminate clinical research or not rely on the results of clinical research for various reasons, including
non-compliance
with regulatory requirements;
 
   
the cost of clinical trials of our drug candidates may be greater than we anticipate; and
 
   
the supply or quality of our drug candidates, companion diagnostics or other materials necessary to conduct clinical trials of our drug candidates may be insufficient or inadequate.
If we are required to conduct additional clinical trials or other testing of our drug candidates beyond those that we currently plan, if we are unable to successfully complete clinical trials of our drug candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if they raise safety concerns, we may (i) be delayed in obtaining regulatory approval for our drug candidates; (ii) obtain approval for indications that are not as broad as intended; (iii) not obtain regulatory approval at all; (iv) have the drug removed from the market after obtaining regulatory approval; (v) be subject to additional post-marketing testing requirements; (vi) be subject to restrictions on how the drug is distributed or used; or (vii) be unable to obtain reimbursement for use of the drug.
Significant clinical trial delays may also increase our development costs and could shorten any periods during which we have the exclusive right to commercialize our drug candidates or allow our competitors to bring drugs to market before we do. This could impair our ability to commercialize our drug candidates and may harm our business and results of operations.
Risks Related to Obtaining Regulatory Approval for Our Drug Candidates
All material aspects of the research, development and commercialization of pharmaceutical products are heavily regulated.
All jurisdictions in which we intend to conduct our pharmaceutical-industry activities regulate these activities in great depth and detail. We intend to focus our activities in the major markets of China and the United States. These jurisdictions strictly regulate the pharmaceutical industry, and in doing so they employ broadly similar regulatory strategies, including regulation of product development and approval, manufacturing, and marketing, sales and distribution of products. However, there are differences in the regulatory regimes that make for a more complex and costly regulatory compliance burden for a company like us that plans to operate in these regions.
 
15

Table of Contents
The process of obtaining regulatory approvals and compliance with appropriate laws and regulations requires the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements at any time during the product development process and approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include: refusal to approve pending applications; withdrawal of an approval; license revocation; clinical hold; voluntary or mandatory product recalls; product seizures; total or partial suspension of production or distribution; injunctions; fines; refusals of government contracts; providing restitution; undergoing disgorgement; or other civil or criminal penalties. Failure to comply with these regulations could have a material adverse effect on our business.
The regulatory approval processes of the NMPA, the FDA and other comparable regulatory authorities are time-consuming and may evolve over time, and if we are ultimately unable to obtain regulatory approval for our drug candidates, our business will be substantially harmed.
The time required to obtain the approval of the NMPA, the FDA and other comparable regulatory authorities is inherently uncertain and depends on numerous factors, including the substantial discretion of the regulatory authorities. Generally, such approvals take many years to obtain following the commencement of
pre-clinical
studies and clinical trials, although they are typically provided within 12 to 18 months after clinical trials are completed. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a drug candidate’s clinical development and may vary among jurisdictions. As of the date of this annual report, we have obtained IND approvals from the NMPA for ten of our drug candidates, felzartamab, olamkicept, efineptakin alfa, lemzoparlimab, uliledlimab, plonmarlimab, eftansomatropin alfa, enoblituzumab, TJ210 and
TJ-CD4B.
In addition, we have obtained IND approvals from the FDA for six of our drug candidates, lemzoparlimab, uliledlimab, plonmarlimab, TJ210,
TJ-L14B
and
TJ-CD4B;
from the TFDA for two of our drug candidates, felzartamab and olamkicept; and from the MFDS for olamkicept. However, we cannot guarantee that we are able to obtain regulatory approvals for our other existing drug candidates or any drug candidates we may discover,
in-license
or acquire and seek to develop in the future.
Our drug candidates could fail to receive the regulatory approval of the NMPA, the FDA or a comparable regulatory authority for many reasons, including, without limitation:
 
   
disagreement with the design or implementation of our clinical trials;
 
   
failure to demonstrate that a drug candidate is safe and effective and potent for its proposed indication;
 
   
failure of our clinical trial results to meet the level of statistical significance required for approval;
 
   
failure of our clinical trial process to pass relevant good clinical practice (“GCP”) inspections;
 
   
failure to demonstrate that a drug candidate’s clinical and other benefits outweigh its safety risks;
 
   
disagreement with our interpretation of data from
pre-clinical
studies or clinical trials;
 
   
insufficient data collected from the clinical trials of our drug candidates to support the submission and filing of a new drug application, or NDA, or other submissions or to obtain regulatory approval;
 
   
failure of our drug candidates to pass current Good Manufacturing Practice (“cGMP”), inspections during the regulatory review process or across the production cycle of our drug;
 
   
failure of our clinical sites to pass audits carried out by the NMPA, the FDA or comparable regulatory authorities, resulting in a potential invalidation of our research data;
 
   
findings by the NMPA, the FDA or comparable regulatory authorities of deficiencies related to our manufacturing processes or the facilities of third-party manufacturers with whom we contract for clinical and commercial supplies;
 
16

Table of Contents
   
changes in approval policies or regulations that render our
pre-clinical
and clinical data insufficient for approval; and
 
   
failure of our clinical trial process to keep up with any scientific or technological advancements required by approval policies or regulations.
The NMPA, the FDA or a comparable regulatory authority may require more information, including additional
pre-clinical
or clinical data, to support approval, which may delay or prevent approval and our commercialization plans. Even if we were to obtain approval, regulatory authorities may approve any of our drug candidates for fewer or more limited indications than we request, grant approval contingent on the performance of costly post-marketing clinical trials, or approve a drug candidate with an indication that is not desirable for the successful commercialization of that drug candidate. Any of the foregoing scenarios could materially harm the commercial prospects of our drug candidates.
The failure to obtain patent term extension and data exclusivity for approved pharmaceutical products could increase the risk of generic competition with our products.
In the United States, the Federal Food, Drug and Cosmetic Act, as amended by the law generally referred to as “Hatch-Waxman,” provides the opportunity for patent-term restoration, meaning a patent term extension of up to five years to reflect patent term lost during certain portions of product development and the FDA regulatory review process. Hatch-Waxman also has a process for patent linkage, pursuant to which the FDA will stay approval of certain
follow-on
applications during the pendency of litigation between the
follow-on
applicant and the patent holder or licensee, generally for a period of 30 months. Finally, Hatch-Waxman provides for statutory exclusivities that can prevent submission or approval of certain
follow-on
marketing applications. For example, federal law provides a five-year period of exclusivity within the United States to the first applicant to obtain approval of a new chemical entity and three years of exclusivity protecting certain innovations to previously approved active ingredients where the applicant was required to conduct new clinical investigations to obtain approval for the modification. Similarly, the United States Orphan Drug Act provides seven years of market exclusivity for certain drugs to treat rare diseases, where the FDA designates the drug candidate as an orphan drug and the drug is approved for the designated orphan indication. These provisions, designed to promote innovation, can prevent competing products from entering the market for a certain period of time after the FDA grants marketing approval for the innovative product.
Depending upon the timing, duration and specifics of any FDA marketing approval process for any drug candidates we may develop, one or more of our U.S. patents, if issued, may be eligible for limited patent term extension under Hatch-Waxman. Hatch-Waxman permits a patent extension term of up to five years as compensation for patent term lost during clinical trials and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14 years from the date of drug approval, only one patent may be extended and only those claims covering the approved drug, a method for using it, or a method for manufacturing it may be extended. However, we may not be granted an extension because of, for example, failing to exercise due diligence during the testing phase or regulatory review process, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents, or otherwise failing to satisfy applicable requirements. Furthermore, the applicable time period or the scope of patent protection afforded could be less than we request.
In China, the PRC Patent Law, which was most recently amended by the Standing Committee of the National People’s Congress on October 17, 2020, and became effective on June 1, 2021, for the first time, generally provides for patent term compensation and patent linkage system. Under the PRC Patent Law, patent term compensation can be obtained for regulatory delays in the review and approval of new drugs but are limited to no more than five years and the total post-marketing patent term of the new drug cannot exceed 14 years, which is similar to the provisions of Hatch-Waxman. However, to be implemented, the patent term compensation requires further promulgation of detailed implementation measures. Depending upon the timing, duration and specifics of any NMPA marketing approval process for any drug candidates we may develop, one or more of our China patents, if issued, may not be eligible for or only be eligible for limited patent term compensation. The PRC Patent Law, for the first time, introduces a system for the early resolution of patent disputes concerning generic drug applications, which is similar to the U.S. patent linkage system. On July 4, 2021, the NMPA and the China National Intellectual Property Administration jointly issued the Implementation Measures for Early Resolution Mechanism of Pharmaceutical Patent Disputes (for Trial Implementation) which sets forth, for the first time, details of how such patent linkage system would be implemented. As the China trial version of patent linkage system was just implemented commencing from July 4, 2021, substantial uncertainties remain as to whether this trial system can effectively block early generic competition with our products. Although the Regulations for Implementation of the Drug Administration Law of the People’s Republic of China has provided
six-year
data exclusivity for a new chemical entity, and Chinese regulators have proposed a framework for integrating data exclusivity into the Chinese regulatory regime in 2018, the system of data exclusivity was not really implemented in practice. Consequently, the absence of currently implemented data exclusivity may result in weaker protection for us against generic competition in China than could be available to us in the United States. If we are unable to obtain patent term extension or the term of any such extension is less than we request, our competitors may obtain approval of competing products following our patent expiration, and our business, financial condition, results of operations, and prospects could be materially harmed.
 
17

Table of Contents
Our drug candidates may cause undesirable adverse events or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval.
Undesirable adverse events caused by our drug candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more restrictive label, a delay or denial of regulatory approval by the NMPA, the FDA or other comparable regulatory authorities, or a significant change in our clinical protocol or even our development plan. In particular, as is the case with drugs treating cancers and auto-immune diseases, it is likely that there may be side effects, such as nausea, fatigue and infusion-related reactions, associated with the use of certain of our drug candidates. Results of our trials could reveal a high and unacceptable severity or prevalence of certain adverse events. In such an event, our trials could be suspended or terminated and the NMPA, the FDA or other comparable regulatory authorities could order us to cease further development of, or deny approval of, our drug candidates for any or all targeted indications. Adverse events related to our drug candidates may affect patient recruitment or the ability of enrolled subjects to complete the trial, and could result in potential liability claims. Any of these occurrences may significantly harm our reputation, business, financial condition and prospects.
Additionally, if we or others identify undesirable side effects caused by those of our existing drug candidates that have received regulatory approval, or our other drug candidates after having received regulatory approval, this may lead to potentially significant negative consequences which include, but are not limited to, the following:
 
   
we may suspend marketing of the drug candidate;
 
   
regulatory authorities may withdraw their approvals of or revoke the licenses for the drug candidate;
 
   
regulatory authorities may require additional warnings on the label;
 
   
the FDA may require the establishment of a Risk Evaluation and Mitigation Strategy, or REMS, or the NMPA or a comparable regulatory authority may require the establishment of a similar strategy that may, for instance, restrict distribution of our drugs and impose burdensome implementation requirements on us;
 
   
we may be required to conduct specific post-marketing studies;
 
   
we could be subjected to litigation proceedings and held liable for harm caused to subjects or patients; and
 
   
our reputation may suffer.
Any of these events could prevent us from achieving or maintaining market acceptance of any particular drug candidate that is approved and could significantly harm our business, results of operations and prospects.
Further, combination therapy, such as using our wholly-owned drug candidates as well as third-party agents, may involve unique adverse events that could be exacerbated compared with adverse events from monotherapies. Results of our trials could reveal a high and unacceptable severity or prevalence of adverse events. These types of adverse events could be caused by our drug candidates and could cause us or regulatory authorities to interrupt, delay or halt clinical trials and may result in a more restrictive indication or the delay or denial of regulatory approval by the NMPA, the FDA or other comparable regulatory authority.
 
18

Table of Contents
If we are unable to obtain the NMPA approval for our drug candidates to be eligible for an expedited registration pathway as innovative drug candidates, the time and cost we incur to obtain regulatory approvals may increase.
The NMPA has mechanisms in place for expedited review and approval for drug candidates that are innovative drug applications, provided such drug or drug candidate has a new and clearly defined structure, pharmacological property and apparent clinical value and has not been marketed anywhere in the world. However, there is no assurance that an innovative drug designation will be granted by the NMPA for any of our drug candidates. Moreover, an innovative drug designation, which is typically granted only towards the end of a drug’s developmental stage, does not increase the likelihood that our drug candidates will receive regulatory approval on a fast-track basis, or at all.
Further, there have been recent regulatory initiatives in China in relation to clinical trial approvals, the evaluation and approval of certain drugs and medical devices and the simplification and acceleration of the clinical trial process.
As a result, the regulatory process in China is evolving and subject to change. Any future policies, or changes to current polices might require us to change our planned clinical study design or otherwise spend additional resources and effort to obtain approval of our drug candidates. In addition, policy changes may contain significant limitations related to use restrictions for certain age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for our drug candidates in the PRC, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of our drug candidates or any other drug candidate that we may
in-license,
acquire or develop in the future.
Even if we receive regulatory approval for our drug candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expenses and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our drug candidates.
If the NMPA, the FDA or a comparable regulatory authority approves any of our drug candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the drug will be subject to extensive and ongoing regulatory requirements on pharmacovigilance. These requirements include submissions of safety and other post-marketing information and reports, registration, random quality control testing, adherence to any chemistry, manufacturing, and controls (“CMC”), variations, continued compliance with current GMPs, and GCPs and potential post-approval studies for the purposes of license renewal.
Any regulatory approvals that we receive for our drug candidates may also be subject to limitations on the approved indicated uses for which the drug may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing studies, including Phase 4 studies for the surveillance and monitoring of the safety and efficacy of the drug.
In addition, once a drug is approved by the NMPA, the FDA or a comparable regulatory authority for marketing, it is possible that there could be a subsequent discovery of previously unknown problems with the drug, including problems with third-party manufacturers or manufacturing processes, or failure to comply with regulatory requirements. If any of the foregoing occurs with respect to our drug products, it may result in, among other things:
 
   
restrictions on the marketing or manufacturing of the drug, withdrawal of the drug from the market, or voluntary or mandatory drug recalls;
 
   
fines, warning letters or holds on our clinical trials;
 
   
refusal by the NMPA, the FDA or comparable regulatory authorities to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of drug license approvals;
 
   
refusal by the NMPA, the FDA or comparable regulatory authorities to accept any of our other IND approvals, NDAs or BLAs;
 
19

Table of Contents
   
drug seizure or detention, or refusal to permit the import or export of drugs; and
 
   
injunctions or the imposition of civil, administrative or criminal penalties.
Any government investigation of alleged violations of law could require us to expend significant time and resources and could generate negative publicity. Moreover, regulatory policies may change or additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our drug candidates. If we are not able to maintain regulatory compliance, we may lose the regulatory approvals that we have already obtained and may not achieve or sustain profitability, which in turn could significantly harm our business, financial condition and prospects.
Illegal and/or parallel imports and counterfeit pharmaceutical products may reduce demand for our future approved drug candidates and could have a negative impact on our reputation and business.
The illegal importation of competing products from countries where government price controls or other market dynamics result in lower prices may adversely affect the demand for our future approved drug candidates and, in turn, may adversely affect our sales and profitability in China and other countries where we commercialize our products. Unapproved foreign imports of prescription drugs are illegal under the current laws of China. However, illegal imports may continue to occur or even increase as the ability of patients and other customers to obtain these lower priced imports continues to grow. Furthermore, cross-border imports from lower-priced markets (which are known as parallel imports) into higher-priced markets could harm sales of our future drug products and exert commercial pressure on pricing within one or more markets. In addition, competent government authorities may expand consumers’ ability to import lower priced versions of our future approved products or competing products from outside China or other countries where we operate. Any future legislation or regulations that increase consumer access to lower priced medicines from outside China or other countries where we operate could have a material adverse effect on our business.
Certain products distributed or sold in the pharmaceutical market may be manufactured without proper licenses or approvals, or be fraudulently mislabeled with respect to their content or manufacturers. These products are generally referred to as counterfeit pharmaceutical products. The counterfeit pharmaceutical product control and enforcement system, particularly in developing markets such as China, may be inadequate to discourage or eliminate the manufacturing and sale of counterfeit pharmaceutical products imitating our products. Since counterfeit pharmaceutical products in many cases have very similar appearances compared with the authentic pharmaceutical products but are generally sold at lower prices, counterfeits of our products could quickly erode the demand for our future approved drug candidates.
In addition, counterfeit pharmaceutical products are not expected to meet our or our collaborators’ rigorous manufacturing and testing standards. A patient who receives a counterfeit pharmaceutical product may be at risk for a number of dangerous health consequences. Our reputation and business could suffer harm as a result of counterfeit pharmaceutical products sold under our or our collaborators’ brand name(s). In addition, thefts of inventory at warehouses, plants or while
in-transit,
which are not properly stored and which are sold through unauthorized channels, could adversely impact patient safety, our reputation and our business.
Risks Related to Commercialization of Our Drug Candidates
Our drug candidates may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.
Even if our drug candidates receive regulatory approval, they may nonetheless fail to gain sufficient market acceptance by physicians and patients and others in the medical community. Physicians and patients may prefer other drugs or drug candidates to ours. If our drug candidates do not achieve an adequate level of acceptance, we may not generate significant revenue from sales of our drugs or drug candidates and may not become profitable.
The degree of market acceptance of our drug candidates, if and only when they are approved for commercial sale, will depend on a number of factors, including, but not limited to:
 
   
the clinical indications for which our drug candidates are approved;
 
20

Table of Contents
   
physicians, hospitals and patients considering our drug candidates as a safe and effective treatment;
 
   
whether our drug candidates have achieved the perceived advantages of our drug candidates over alternative treatments;
 
   
the prevalence and severity of any side effects;
 
   
product labeling or package insert requirements of the NMPA, the FDA or other comparable regulatory authorities;
 
   
limitations or warnings contained in the labeling approved by the NMPA, the FDA or other comparable regulatory authorities;
 
   
timing of market introduction of our drug candidates as well as competitive drugs;
 
   
cost of treatment in relation to alternative treatments;
 
   
availability of adequate coverage and reimbursement under the national and provincial reimbursement drug lists in the PRC, or from third-party payors and government authorities in the United States or any other jurisdictions;
 
   
willingness of patients to pay any
out-of-pocket
expenses in the absence of coverage and reimbursement by third-party payors and government authorities;
 
   
relative convenience and ease of administration, including as compared with alternative treatments and competitive therapies; and
 
   
the effectiveness of our sales and marketing efforts.
If our drug candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals or others in the medical community, we will not be able to generate significant revenue or become profitable. Even if our drugs achieve market acceptance, we may not be able to maintain such market acceptance over time if new products or technologies are introduced which are more favorably received than our drugs, are more cost effective or render our drugs obsolete.
We face intense competition and rapid technological change and the possibility that our competitors may develop therapies that are similar, more advanced, or more effective than ours, which may adversely affect our financial condition and our ability to successfully commercialize our drug candidates.
The biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change. While our exclusive focus is to develop drug candidates with potential to become novel or highly differentiated drugs, we continue to face competition with respect to our current drug candidates, and will face competition with respect to any drug candidates that we may seek to develop or commercialize in the future. Our competitors include major pharmaceutical companies, specialty pharmaceutical companies and biotechnology companies worldwide. We are developing our drug candidates for the treatment of cancer in competition with a number of large biopharmaceutical companies that currently market and sell drugs or are pursuing the development of drugs also for the treatment of cancer. Some of these competitive drugs and therapies are based on scientific approaches that are the same as or similar to our approach, and others are based on entirely different approaches. For details, see “Item 4. Information on the Company—B. Business Overview—Our Drug Pipeline.” Potential competitors further include academic institutions, government agencies and other public and private research organizations that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.
Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. As a result, these companies may obtain regulatory approval from the NMPA, the FDA or other comparable regulatory authorities more rapidly than we are able to and may be more effective in selling and marketing their products as well. For example, the NMPA has recently accelerated market approval of drugs for diseases with high unmet medical need. In particular, the NMPA may review and approve drugs that have gained regulatory market approval in the United States, the European Union or Japan in the recent ten years without requiring further clinical trials in China. This may lead to potential increased competition from drugs which have already obtained approval in other jurisdictions.
 
 
21

Table of Contents
Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors may succeed in developing, acquiring, or licensing on an exclusive basis, products that are more effective or less costly than any drug candidate that we may develop, or achieve earlier patent protection, regulatory approval, product commercialization, and market penetration than we do. Additionally, technologies developed by our competitors may render our potential drug candidates uneconomical or obsolete, and we may not be successful in marketing our drug candidates against competitors.
The manufacture of biopharmaceutical products is a complex process which requires significant expertise and capital investment, and if we encounter problems in sourcing manufacturing capabilities or manufacturing our future products, our business could suffer.
We have limited experience in managing the manufacturing process. The manufacture of biopharmaceutical products is a complex process, in part due to strict regulatory requirements. We have invested in a comprehensive biologics manufacturing facility in Hangzhou, China (the “Hangzhou Facility”) as part of our strategic plan to become a specialty biopharma company. We have taken concrete steps to execute this plan. These steps include detailed operational planning for the facility, actions taken to secure an appropriate site, and negotiations with external financing providers. The construction of the Hangzhou Facility commenced in April 2021. The Hangzhou Facility targets to have a pilot capacity of two production lines (one line configured with 2 x 2,000L and the other line with 1 x 2,000L) around the middle of 2022 and commercially progressive capacity up to 8 x 4,000L to begin operation by the end of 2023 or early 2024. However, the investment for building this new biologics manufacturing facility that is compliant with cGMP regulations will be a significant upfront cost for us. In turn, this could materially harm our commercialization plans.
In addition, problems may arise during the manufacturing process for a variety of reasons, including equipment malfunction, failure to follow specific protocols and procedures, problems with raw materials, delays related to the construction of new facilities or expansion of any future manufacturing facilities, including changes in manufacturing production sites and limits to manufacturing capacity due to regulatory requirements, changes in the types of products produced, increases in the prices of raw materials, physical limitations that could inhibit continuous supply,
man-made
or natural disasters and environmental factors. If problems arise during the production of a batch of future products, that batch of future products may have to be discarded and we may experience product shortages or incur added expenses. This could, among other things, lead to increased costs, lost revenue, damage to customer relationships, time and expense spent investigating the cause and, depending on the cause, similar losses with respect to other batches or products. If problems are not discovered before such product is released to the market, recall and product liability costs may also be incurred.
We have no experience in launching and marketing drug candidates. We may not be able to effectively build and manage our sales network, or benefit from third-party collaborators’ sales network.
We currently have no sales, marketing or commercial product distribution capabilities and have no experience in marketing drugs. We intend to develop an
in-house
marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other biopharmaceutical companies to recruit, hire, train and retain marketing and sales personnel.
If we are unable or decide not to establish internal sales, marketing and commercial distribution capabilities for any or all of the drugs we develop, we will likely pursue collaborative arrangements regarding the sales and marketing of our drugs. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or, if we are able to do so, that they will have effective sales forces. Any revenue we receive will depend on the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized our drug candidates ourselves. We will also face competition in our search for third parties to assist us with the sales and marketing efforts of our drug candidates.
 
22

Table of Contents
There can be no assurance that we will be able to develop
in-house
sales and commercial distribution capabilities or establish or maintain relationships with third-party collaborators to successfully commercialize any product, and as a result, we may not be able to generate product sales revenue.
Even if we are able to commercialize any approved drug candidates, reimbursement may be limited or unavailable in certain market segments for our drug candidates, and we may be subject to unfavorable pricing regulations, which could harm our business.
The regulations that govern regulatory approvals, pricing and reimbursement for new therapeutic products vary widely from country to country. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or licensing approval is granted. In some
non-U.S.
markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain regulatory approval for a drug in a particular country, but then be subject to price regulations that delay our commercial launch of the drug and negatively impact the revenues we are able to generate from the sale of the drug in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more drug candidates, even if our drug candidates obtain regulatory approval. For example, according to a statement, Opinions on Reforming the Review and Approval Process for Pharmaceutical Products and Medical Devices, issued by the PRC State Council in August 2015, the enterprises applying for new drug approval will be required to undertake that the selling price of new drug on PRC mainland market will not be higher than the comparable market prices of the product in its country of origin or PRC’s neighboring markets, as applicable.
Our ability to commercialize any drugs successfully also will depend in part on the extent to which reimbursement for these drugs and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the global healthcare industry is cost containment. Government authorities and these third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any drug that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Reimbursement may impact the demand for, or the price of, any drug for which we obtain regulatory approval. Obtaining reimbursement for our drugs may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any drug candidate that we successfully develop.
There may be significant delays in obtaining reimbursement for approved drug candidates, and coverage may be more limited than the purposes for which the drug candidates are approved by the NMPA, the FDA or other comparable regulatory authorities. Moreover, eligibility for reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim payments for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Payment rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on payments allowed for lower cost drugs that are already reimbursed, and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future weakening of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Our inability to promptly obtain coverage and profitable payment rates from both government-funded and private payors for any future approved drug candidates and any new drugs that we develop could have a material adverse effect on our business, our operating results, and our overall financial condition.
 
23

Table of Contents
Current and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our drug candidates and affect the prices we may obtain.
In the United States and certain other jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our drug candidates, restrict post-approval activities and affect our ability to sell profitably any drug candidates for which we obtain marketing approval.
The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, became law. The ACA is a sweeping law intended to broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, add new transparency requirements for the healthcare and health insurance industries, impose new taxes and fees on the health industry and impose additional health policy reforms. The following sets forth the major provisions of the ACA that may affect our drug candidates:
 
   
an annual, nondeductible fee on any entity that manufactures or imports specified branded prescription drugs and biologic products;
 
   
an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program;
 
   
expansion of healthcare fraud and abuse laws, including the False Claims Act and the Anti-Kickback Statute, new government investigative powers, and enhanced penalties for noncompliance;
 
   
a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50%
point-of-sale
discounts off negotiated prices;
 
   
extension of manufacturers’ Medicaid rebate liability;
 
   
expansion of eligibility criteria for Medicaid programs;
 
   
expansion of the entities eligible for discounts under the Public Health Service Act’s pharmaceutical pricing program;
 
   
new requirements to report to CMS financial arrangements with physicians and teaching hospitals;
 
   
a new requirement to annually report to the FDA drug samples that manufacturers and distributors provide to physicians; and
 
   
a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals, if any, of our drug candidates may be. In addition, increased scrutiny by the U.S. Congress of the FDA’s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing conditions and other requirements.
As we
out-license
some of our commercialization rights and engage in other forms of collaboration worldwide, including conducting clinical trials abroad, we may be exposed to specific risks of conducting our business and operations in international markets.
Markets outside of China form an important component of our growth strategy, as we
out-license
some of our commercialization rights to third parties outside the PRC and conduct certain of our clinical trials abroad. If we fail to obtain applicable licenses or fail to enter into strategic collaboration arrangements with third parties in these markets, or if these collaboration arrangements turn out unsuccessful, our revenue-generating growth potential will be adversely affected.
 
24

Table of Contents
Moreover, international business relationships subject us to additional risks that may materially adversely affect our ability to attain or sustain profitable operations, including:
 
   
efforts to enter into collaboration or licensing arrangements with third parties in connection with our international sales, marketing and distribution efforts may increase our expenses or divert our management’s attention from the acquisition or development of drug candidates;
 
   
changes in a specific country’s or region’s political and cultural climate or economic condition;
 
   
differing regulatory requirements for drug approvals and marketing internationally;
 
   
difficulty of effective enforcement of contractual provisions in local jurisdictions;
 
   
potentially reduced protection for intellectual property rights;
 
   
potential third-party patent rights;
 
   
unexpected changes in tariffs, trade barriers and regulatory requirements;
 
   
economic weakness, including inflation or political instability;
 
   
compliance with tax, employment, immigration and labor laws for employees traveling abroad;
 
   
the effects of applicable
non-PRC
tax structures and potentially adverse tax consequences;
 
   
currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incidental to doing business in another country;
 
   
workforce uncertainty and labor unrest;
 
   
the potential for
so-called
parallel importing, which is what happens when a local seller, faced with high or higher local prices, opts to import goods from an international market with low or lower prices rather than buying them locally;
 
   
failure of our employees and contracted third parties to comply with Office of Foreign Assets Control rules and regulations and the Foreign Corrupt Practices Act of the United States, and other applicable rules and regulations;
 
   
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
 
   
business interruptions resulting from
geo-political
actions, including war and terrorism, or natural disasters, including earthquakes, volcanoes, typhoons, floods, hurricanes and fires.
These and other risks may materially adversely affect our ability to attain or sustain revenue from international markets.
If safety, efficacy, or other issues arise with any medical product that is used in combination with our drug candidates, we may be unable to market such drug candidate or may experience significant regulatory delays or supply shortages, and our business could be materially harmed.
We plan to develop certain of our drug candidates for use as a combination therapy. If the NMPA, the FDA or another comparable regulatory agency revokes its approval of another therapeutic we use in combination with our drug candidates, we will not be able to market our drug candidates in combination with such revoked therapeutic. If safety or efficacy issues arise with these or other therapeutics that we seek to combine with our drug candidates in the future, we may experience significant regulatory delays, and we may be required to redesign or terminate the applicable clinical trials. In addition, if manufacturing or other issues result in a supply shortage of any component of our combination drug candidates or if we cannot secure supply of any component of our drug candidates at commercially reasonable or acceptable prices, we may not be able to complete clinical development of our drug candidates on our current timeline or within our current budget, or at all.
 
25

Table of Contents
Lack of third-party combination drugs may materially and adversely affect demand for our drugs.
Our drug candidates may be administered in combination with drugs of other pharmaceutical companies as one regimen. In addition, we often use such third-party drugs in our development and clinical trials as controls for our studies. As a result, both the results of our clinical trials and the sales of our drugs may be affected by the availability of these third-party drugs. If other pharmaceutical companies discontinue these combination drugs, regimens that use these combination drugs may no longer be prescribed, and we may not be able to introduce or find an alternative drug to be used in combination with our drugs at all or in a timely manner and on a cost-effective basis. As a result, demand for our drugs may be lowered, which would in turn materially and adversely affect our business and results of operations.
Risks Related to Our Reliance on Third Parties
As we rely on third parties to conduct our
pre-clinical
studies and clinical trials, if we lose our relationships with these third parties or if they do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval for or commercialize our drug candidates and our business could be substantially harmed.
We have relied on and plan to continue to rely on third-party contract research organization (“CROs”) to monitor and manage data for some of our ongoing
pre-clinical
and clinical programs. We rely on these parties for the execution of our
pre-clinical
and clinical trials, and control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities.
We also rely on third parties to assist in conducting our
pre-clinical
studies in accordance with Good Laboratory Practices (“GLP”). We and our CROs are required to comply with GCP, GLP and other regulatory regulations and guidelines enforced by the NMPA, the FDA and comparable foreign regulatory authorities for all of our drug candidates in clinical development. Regulatory authorities enforce these GCP, GLP or other regulatory requirements through periodic inspections of trial sponsors, investigators and trial sites. If we or any of our CROs fail to comply with applicable GCP, GLP or other regulatory requirements, the relevant data generated in our clinical trials may be deemed unreliable and the NMPA, the FDA or other comparable regulatory authorities may require us to perform additional clinical studies before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP requirements. In addition, our clinical trials must be conducted with drug candidates or products produced under cGMP requirements. Failure to comply with these regulations may require us to repeat
pre-clinical
and clinical trials, which would delay the regulatory approval process.
Our CROs have the right to terminate their agreements with us in the event of an unrectified material breach. If any of our relationships with our third-party CROs is terminated, we may not be able to (i) enter into arrangements with alternative CROs or do so on commercially reasonable terms or (ii) meet our desired clinical development timelines. In addition, there is a natural transition period when a new CRO commences work, and the new CRO may not provide the same type or level of services as the original provider and data from our clinical trials may be compromised as a result. There is also a need for relevant technology to be transferred to the new CRO, which may take time and further delay our development timelines.
Except for remedies available to us under our agreements with our CROs, we cannot control whether or not our CROs devote sufficient time and resources to our ongoing clinical, nonclinical and
pre-clinical
programs. If our CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines or if the quality or accuracy of the clinical data they obtain is compromised due to their failure to adhere to our clinical protocols, regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. As a result, our results of operations and the commercial prospects for our drug candidates would be harmed and our costs could increase. In turn, our ability to generate revenues could be delayed or compromised.
 
26

Table of Contents
Because we rely on third parties, our internal capacity to perform these functions is limited. Outsourcing these functions involves certain risks that third parties may not perform to our standards, may not produce results in a timely manner or may fail to perform at all. In addition, the use of third-party service providers requires us to disclose our proprietary information to these third parties, which could increase the risk that such information will be misappropriated. We currently have a small number of employees, which limits the internal resources we have available to identify and monitor our third-party service providers. To the extent we are unable to identify and successfully manage the performance of third-party service providers in the future, our business may be adversely affected. Though we carefully manage our relationships with our CROs, there can be no assurance that we will not encounter similar challenges or delays in the future or that these delays or challenges will not have a material adverse impact on our business, financial condition and prospects.
We expect to rely on third parties to manufacture at least a portion of our drug candidate supplies, and we intend to rely on third parties for at least a portion of the manufacturing process of our drug candidates, if approved. Our business could be harmed if those third parties fail to provide us with sufficient quantities of product or fail to do so at acceptable quality levels or prices.
Although we plan to secure a facility that we can control for clinical-scale manufacturing and processing of our drug candidates, we intend to also partially rely on third-party vendors to manufacture supplies and process our drug candidates. We have not yet manufactured or processed our drug candidates on a commercial scale and may not be able to do so for any of our drug candidates. We have limited experience in managing the manufacturing process, and our process may be more difficult or expensive than the approaches currently in use.
Our anticipated reliance on third-party manufacturers exposes us to certain risks, including, but not limited to, the following:
 
   
we may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the NMPA, the FDA or other comparable regulatory authorities must approve any manufacturers as part of their regulatory oversight of our drug candidates. This approval would require new testing and cGMP-compliance inspections by the NMPA, the FDA or other comparable regulatory authorities. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our drugs;
 
   
our contract manufacturers may have little or no experience with manufacturing our drug candidates, and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our drug candidates;
 
   
our contract manufacturers may have limited capacity or limited manufacturing slots, which may affect the timeline for the production of our drugs;
 
   
our contract manufacturers might be unable to timely manufacture our drug candidates or produce the quantity and quality required to meet our clinical and commercial needs, if any;
 
   
contract manufacturers may not be able to execute our manufacturing procedures and other logistical support requirements appropriately;
 
   
our future contract manufacturers may not perform as agreed, may not devote sufficient resources to our drugs, or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our drugs;
 
   
our contract manufacturers are subject to ongoing periodic unannounced inspections by the NMPA and the FDA to ensure strict compliance with cGMP and other government regulations in the PRC and the United States, respectively, and by other comparable regulatory authorities for corresponding regulatory requirements. We do not have control over third-party manufacturers’ compliance with these regulations and requirements;
 
   
we may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our drugs;
 
27

Table of Contents
   
our contract manufacturers could breach or terminate their agreements with us;
 
   
our contract manufacturers may be unable to sustain their business and become bankrupt as a result;
 
   
raw materials and components used in the manufacturing process, particularly those for which we have no other source or supplier, may not be available or may not be suitable or acceptable for use due to material or component defects;
 
   
products and components from our third-party manufacturers may be subject to additional customs and import charges, which may cause us to incur delays or additional costs as a result;
 
   
our contract manufacturers and critical reagent suppliers may be subject to inclement weather, as well as natural or
man-made
disasters; and
 
   
our contract manufacturers may have unacceptable or inconsistent product quality success rates and yields.
Each of these risks could delay or prevent the completion of our clinical trials or the approval of any of our drug candidates by the NMPA, the FDA or other comparable regulatory authorities, result in higher costs or adversely impact the commercialization of our drug candidates. In addition, we will rely on third parties to perform certain specification tests on our drug candidates prior to delivery to patients. If these tests are not appropriately done and test data is not reliable, patients could be put at risk of serious harm and the NMPA, the FDA or other comparable regulatory authorities could place significant restrictions on our company until deficiencies are remedied.
The manufacture of biopharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Currently, our drug raw materials for our manufacturing activities are supplied by multiple source suppliers. We have agreements for the supply of drug materials with manufacturers or suppliers that we believe have sufficient capacity to meet our demands. In addition, we believe that adequate alternative sources for such supplies exist. However, there is a risk that, if supplies are interrupted, our business would be materially harmed.
Manufacturers of biopharmaceutical products often encounter difficulties in production, particularly in scaling up or out, validating the production process, and assuring high reliability of the manufacturing process, including the absence of contamination. These problems include logistics and shipping, difficulties with production costs and yields, quality control, including stability of the product, product testing, operator error and availability of qualified personnel, as well as compliance with strictly enforced regulations in the PRC, the United States and other applicable jurisdictions. Further, if contaminants are discovered in the supply of our drug candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time for us to investigate and remedy the contamination. There can be no assurance that any stability failures or other issues relating to the manufacture of our drug candidates will not occur in the future. Additionally, our contract manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environment. If our contract manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our drug candidate to patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of our clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to begin new clinical trials at additional expense or terminate clinical trials completely.
 
28

Table of Contents
We have entered into collaborations and may form or seek collaborations or strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.
We may form or seek strategic alliances, create joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our drug candidates and any future drug candidates that we may develop. Any of these relationships may require us to incur recurring or
non-recurring
expenses and other charges, increase our near and long-term expenditures, issue securities that dilute the value of our ADSs, or disrupt our management and business. For example, we have entered into a license and collaboration agreement with MorphoSys AG (“MorphoSys”), pursuant to which we
in-licensed
from MorphoSys the development and commercialization rights of felzartamab in Greater China. Another example is our collaboration with AbbVie. In September 2020, we granted AbbVie a global license, excluding mainland China, Hong Kong and Macau, to develop and commercialize lemzoparlimab (as well as certain other compounds directed against CD47), and we will retain all rights to develop and commercialize lemzoparlimab in mainland China, Hong Kong and Macau.
The effectiveness of the contract with AbbVie is subject to our performance of certain contractual obligations and regulatory approval; such approval may not be obtained or may be delayed, which could result in a detrimental effect on our collaboration. For a more detailed discussion, please see “Item 4. Information on the Company—B. Business—Licensing and Collaboration Arrangements—B. Out-Licensing Arrangements—License and Collaboration Agreement with AbbVie.” In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our drug candidates because they may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our drug candidates as having the requisite potential to demonstrate safety and efficacy. If and when we collaborate with a third party for the development and commercialization of a drug candidate, we can expect to relinquish some or all of the control over the future success of that drug candidate to the third party.
Further, collaborations involving our drug candidates are subject to specific risks, which include, but are not limited to, the following:
 
   
collaborators have significant discretion in determining the efforts and resources that they will apply to a collaboration;
 
   
collaborators may not pursue the development and commercialization of our drug candidates or may elect not to continue or renew the development or commercialization programs based on clinical trial results, change in their strategic focus due to the acquisition of competitive drugs, availability of funding, or other external factors, such as a business combination that diverts resources or creates competing priorities;
 
   
collaborators may delay clinical trials, provide insufficient funding for a clinical trial, discontinue a clinical trial, repeat or conduct new clinical trials, or require a new formulation of a drug candidate for clinical testing;
 
   
collaborators could independently develop, or develop with third parties, drugs that compete directly or indirectly with our drug candidates or future drugs;
 
   
collaborators with marketing and distribution rights to one or more of our drug candidates or future drugs may not commit sufficient resources to their marketing and distribution;
 
   
collaborators may not properly maintain or defend our intellectual property rights or may use our intellectual property or proprietary information in a way that gives rise to actual or threatened litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential liability;
 
   
collaborators may not always be cooperative or responsive in providing their services in a clinical trial;
 
   
disputes may arise between us and a collaborator that cause a delay or termination of the research, development or commercialization of our drug candidates, or that result in costly litigation or arbitration that diverts management attention and resources;
 
   
collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable drug candidates; and
 
   
collaborators may own or
co-own
intellectual property covering our drug candidates or future drugs that results from our collaborating with them, and in such cases, we would not have the exclusive right to commercialize such intellectual property.
 
29

Table of Contents
As a result, if we enter into collaboration agreements and strategic partnerships or license our drugs, we may not be able to realize the benefit of such transactions if we are unable to address the risks mentioned above and successfully integrate these agreements or partnerships with our existing operations and company culture, which could delay our timelines or otherwise adversely affect our business. For example, disputes have arisen between Tracon Pharmaceuticals, Inc. (“Tracon”) and us in relation to the collaboration agreements to co-develop our proprietary CD73 antibody, TJD5 (the “TJD5 Agreement”) and to co-develop up to five bispecific antibodies (the “BsAbs Agreement”). See “Item 8. Financial Information—A. Consolidated Statements and Other Financial Information—Legal Proceedings” for details. The disputes relating to the TJD5 Agreement and the BsAbs Agreement are the subject of a binding arbitration proceeding under the Rules of Arbitration of the International Chamber of Commerce before an arbitration tribunal. The arbitration tribunal held a hearing on the merits in February 2022. As of the date of this annual report, the disputes have not been resolved and we expect that the decision from the arbitration tribunal may be available in late 2022. We are not able to predict the likely outcome of such disputes. Any adverse outcome as a result of the arbitration tribunal’s decision, or any further disputes in connection thereof, could have an adverse effect on our business prospects, financial condition, results of operation and reputation.
Neither can we be certain that, following a strategic transaction or license, we will be able to achieve the revenue or specific net income that justifies such transaction. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a drug candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our drug candidates or bring them to market and generate product sales revenue, which would harm our business, financial condition, results of operations and prospects.
Risks Related to Our Intellectual Property
If we are unable to obtain and maintain patent and other intellectual property protection for our drug candidates, or if the scope of such intellectual property rights obtained is not sufficiently broad, third parties could develop and commercialize products and technologies similar or identical to ours and compete directly against us, and our ability to successfully commercialize any product or technology may be adversely affected.
Our success depends in large part on our ability to protect our proprietary technology and drug candidates from competition by obtaining, maintaining, defending and enforcing our intellectual property rights, including patent rights. As of December 31, 2021, our owned patent portfolio consisted of 47 issued patents and 250 patent applications primarily in connection with the drug candidates in our Global Portfolio, including 21 Patent Cooperation Treaty (“PCT”) patent applications, 15 U.S. patent applications, 16 PRC patent applications and 198 patent applications in other jurisdictions. In addition, as of December 31, 2021, we
in-licensed
the Greater China and Korea rights relating to 28 issued patents and 39 pending patent applications primarily in connection with felzartamab, eftansomatropin alfa, olamkicept, enoblituzumab, efineptakin alfa and TJ210. We seek to protect the drug candidates and technology that we consider commercially important by filing patent applications in China, the United States and other countries or regions, relying on trade secrets or pharmaceutical regulatory protection or employing a combination of these methods. This process is expensive and time-consuming, and we or our licensors may not be able to file and prosecute all necessary or desirable patent applications in all jurisdictions at a reasonable cost or in a timely manner. It is also possible that we or our licensors will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.
The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or drug candidates or which effectively prevent others from commercializing competitive technologies and drug candidates. The patent examination process may require us or our licensors to narrow the scope of the claims of our or our licensors’ pending and future patent applications, which may limit the scope of patent protection that may be obtained. We cannot assure that all of the potentially relevant prior art relating to our patents and patent applications has been found. If such prior art exists, it can invalidate a patent or prevent a patent application from being issued as a patent.
 
30

Table of Contents
Even if patents do issue on any of these applications, there can be no assurance that a third party will not challenge their validity, enforceability, or scope, which may result in the patent claims being narrowed or invalidated, or that we will obtain sufficient claim scope in those patents to prevent a third party from competing successfully with our drug candidates. We may become involved in interference, inter partes review, post grant review, ex parte reexamination, derivation, opposition or similar other proceedings challenging our patent rights or the patent rights of others. An adverse determination in any such proceeding could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or drug candidates and compete directly with us, or result in our inability to manufacture or commercialize drug candidates without infringing third-party patent rights. Thus, even if our patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage.
Our competitors may be able to circumvent our patents by developing similar or alternative technologies or drug candidates in a
non-infringing
manner. The issuance of a patent is not conclusive as to its scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and other countries. Such challenges may result in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop or prevent us from stopping others from using or commercializing similar or identical technology and drug candidates, or limit the duration of the patent protection of our technology and drug candidates. Given the amount of time required for the development, testing and regulatory review of new drug candidates, patents protecting such assets might expire before or shortly after such assets are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing drug candidates similar or identical to ours.
Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. Under the America Invents Act (“AIA”) enacted in 2011, the United States moved to this
first-to-file
system in early 2013 from the previous system under which the first to make the claimed invention was entitled to the patent. Assuming the other requirements for patentability are met, the first to file a patent application is entitled to the patent. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the inventions claimed in our patents or pending patent applications, or that we were the first to file for patent protection of such inventions.
We enjoy only limited geographical protection with respect to certain patents and may not be able to protect our intellectual property rights throughout the world, including in the PRC.
Filing and prosecuting patent applications and defending patents covering our drug candidates in all countries throughout the world could be prohibitively expensive. Competitors may use our and our licensors’ technologies in jurisdictions where we have not obtained patent protection to develop their own drug candidates and, further, may export otherwise infringing drug candidates to territories, including the PRC, where we and our licensors have patent protection, but enforcement rights are not as strong as that in the United States or Europe. These drug candidates may compete with our drug candidates, and our and our licensors’ patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
The laws of some jurisdictions, including the PRC, do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and Europe, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing dr